MAY 2016
MEDICAL UNIVERSITY OF SOUTH CAROLINA
COLLEGE OF MEDICINE
CURRICULUM VITAE
NAME: Elizabeth Garrett-Mayer BIRTH DATE: August 16, 1972
HOME ADDRESS: Mt Pleasant, SC 29466 HOME PHONE: 843-416-8243
OFFICE ADDRESS: OFFICE PHONE: 843-792-7764
Rm 118G OFFICE FAX: 843-792-4233
Hollings Cancer Center EMAIL: [email protected]
86 Jonathan Lucas St. WEBPAGE: http://people.musc.edu/~elg26
Charleston, SC 29466
CITIZENSHIP AND/OR VISA INFORMATION: United States Citizen
EDUCATION:
INSTITUTION/LOCATION YEARS DEGREE/DATE FIELDS OF STUDY
Bowdoin College, Brunswick, ME 1990-1994 B.A., May 1994 Mathematics, Economics (Minor: Classics)
Johns Hopkins University, Baltimore, MD 1994-2000 PhD., Feb 2000 Biostatistics
Dissertation: Graphical Diagnostic Tools for Standard Latent Class and Latent Class Regression Model Assessment with an
Application in Describing Depression and Validating Diagnostic Criteria for Depression.
Advisor: Scott L. Zeger
Thesis Committee: William Eaton, Scott Zeger, Kung-Yee Liang, Peter Pronovost, Leon Gordis
FACULTY APPOINTMENTS:
YEARS RANK INSTITUTION DEPARTMENT
2000-2001 Instructor Johns Hopkins University Oncology
2000-2001 Joint Appt., Instructor Johns Hopkins University Biostatistics
2001-2007 Assistant Professor Johns Hopkins University Oncology
2001-2007 Joint Appt., Asst. Professor Johns Hopkins University Biostatistics
2007- 2012 Associate Professor Medical University of South Carolina Public Health Sciences*
2012- 2014 Professor Medical University of South Carolina Public Health Sciences*
2015 – present Professor with tenure Medical University of South Carolina Public Health Sciences* * formerly the Department of Biostatistics, Bioinformatics and Epidemiology; and formerly the Division of Biostatistics and Epidemiology in the Department of Medicine.
ADMINISTRATIVE APPOINTMENTS: YEARS POSITION INSTITUTION DEPARTMENT
2007 -- present Director of Biostatistics Hollings Cancer Center, MUSC
2015 – present Biostatistics & Bioinformatics Division Director Medical University of South Carolina Public Health Sciences
MEMBERSHIP IN PROFESSIONAL/SCIENTIFIC SOCIETIES:
NATIONAL SOCIETIES MEMBERSHIP
The American Statistical Association
The International Biometric Society
The Society for Clinical Trials
American Association of Cancer Research
American Society of Clinical Oncology
Translational Breast Cancer Research Consortium
NATIONAL SOCIETIES OFFICES HELD
Track Leader for Biostatistics, Scientific Planning Ctte, American Society of Clinical Oncology, 2009
ELIZABETH GARRETT-MAYER PAGE 2 OF 31 MAY 16
Local Societies MEMBERSHIP:
South Carolina Chapter of the American Statistical Association
EDITORIAL POSITIONS:
ASSOCIATE EDITOR, Clinical Trials, 2007 – present
EDITORIAL BOARD MEMBER, Cancer, 2014 - present
REFEREE FOR PEER-REVIEW JOURNALS:
1. Alzheimers and Dementia,
2. American Journal of Epidemiology
3. Annals of Internal Medicine
4. Annals of Oncology
5. Antimicrobial Resistance and Infection Control
6. Behaviormetrika
7. Bioinformatics
8. Biometrical Journal
9. Biometrics
10. Biometrika
11. Biostatistics
12. Breast Cancer Research and Treatment
13. Cancer Management
14. Cancer Research
15. Clinical Cancer Research
16. Clinical Investigation
17. Clinical Trials
18. Contemporary Clinical Trials
19. Functional and Integrative Genomics
20. JAMA Oncology
21. Journal of Clinical Oncology
22. Journal of the National Cancer Institute
23. The Journal of Nutrition
24. Journal of Applied Statistics
25. Journal of the American Statistical Association (JASA)
26. Journal of Biopharmaceutical Statistics
27. Journal of Clinical Oncology
28. Journal of the National Cancer Institute
29. Journal of Probability and Statistics
30. Journal of Psychosocial Oncology
31. Journal of the Royal Statistical Society
32. Molecular Cancer Therapeutics
33. Pharmaceutical Statistics
34. PLOS ONE
35. Statistics in Medicine
36. Trends in Pharmacological Sciences
NATIONAL ADVISORY BOARD ACTIVITIES AND COMMITTEES
ENAR International Biometrics Society Student Paper Awards Committee, 2006-2009
Translational Breast Cancer Research Consortium, Co-leader of Biostatistics, 2007-present
Scientific Planning Committee, American Society of Clinical Oncology, 2007-2010
National Cancer Institute and Investigational Drug Steering Committee, Task Force on Clinical Trial Design, 2008-2010.
Education Committee for AACR Annual Meeting, Chicago, IL 2011- 2012
Program Committee, Society for Clinical Trials Annual Meeting, Biometrics Section. Miami, FL. May 2012.
American Society of Clinical Oncology, Breast Cancer Working Group Member for the “Blueprint Project: Determining when
Outcomes of Trials Are Clinically Meaningful”, 2012- 2014.
National Cancer Institute’s Investigational Drug Steering Committee (IDSC), Biostatistics Subject Matter Expert, 2012-present.
National Cancer Institute’s Investigational Drug Steering Committee (IDSC), Clinical Trial Design Task Force, 2013-present.
American Society of Clinical Oncology, Cancer Research Committee. 2014 - 2017
American Society of Clinical Oncology, Scientific Program Committee (Biostatistics). 2015 – 2018.
American Society of Clinical Oncology, Cancer Research Committee. 2015 – 2018.
ELIZABETH GARRETT-MAYER PAGE 3 OF 31 MAY 16
Friends of Cancer Research, Working Group for 8th Annual Conference on Clinical Cancer Research. Sept – Nov 2015.
American Society of Clinical Oncology -Friends of Cancer Research Eligibility Criteria Planning Group and Working Group.
December 2015 – present
American Association of Cancer Research, Continuing Medical Education Committee. 2016 – 2018.
Accelerating Anti-Cancer Agent Development and Validation Workshop, Fundamentals Course (for training Patient Advocates).
Planning Committee Member.
NATIONAL GRANT REVIEW ACTIVITIES
2002 Reviewer, California Breast Cancer Research Program Grant Applications
2007 Reviewer, Susan G. Komen for the Cure Focused Areas of Study Program Grants
2008 Reviewer, Susan G. Komen for the Cure Promise Grants
2009 - 2011 Member & Reviewer, Scientific Peer Review Ctte, Susan G. Komen for the Cure, Promise Grants
2009, Jun Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)
2009, Sep Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)
2009 Reviewer, Susan G. Komen for the Cure, Targeted Therapies
2010, Feb Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)
2011, Jan Reviewer, Susan G. Komen for the Cure Career Catalyst Research Award Program
2011, Jan Reviewer, The ASCO Cancer Foundation Career Development and Young Investigator Awards Program
2011, Sep Reviewer, Clinical Oncology Study Section, National Institutes of Health.
2011- 2014 Executive Committee Member, Grants Selection Committee, Conquer Cancer Foundation of the
American Society of Clinical Oncology
2011, Oct Ad Hoc Reviewer, National Cancer Institute, Clinical Oncology Study Section.
2011, Feb Ad Hoc Reviewer, National Cancer Institute, Clinical Oncology Study Section
2012 – 2016 Member, National Cancer Institute, Clinical Oncology Study Section
2014, Dec Peer Review Panel Member, Department of Defense Congressionally Directed Medical Research Programs
LOCAL GRANT REVIEW
MUSC-Wake Forest Cancer Prevention and Control Pilot Project Review Committee, 2007
American Cancer Society Institutional Research Grants, 2007 – present
Hollings Cancer Center Translational Research Grants, 2008-2011
Hollings Cancer Center Tobacco Control and Tobacco-Caused Cancer Research Grants, 2011
Hollings Cancer Center Pilot Projects, 2012-present
PROFESSIONAL MEETING SESSION CHAIR
Organizer and Chair, Eastern North American Region (ENAR) International Biometrics Society Annual Meeting: "Methods
for Combining Gene Expression Datasets from Different Studies", 2004
Organizer and Chair, Society of Clinical Trials Annual Meeting. “Frequentist, Bayesian and Likelihood Designs for a Phase
II Cancer Trial with a Time-to-Event Endpoint: Head to Head Comparison of Three Philosophies of Trial Design.”
Vancouver, BC. May 17, 2011.
Organizer and Chair, American Association of Cancer Research Annual Meeting. “Phase II Trials: Are We Asking Too
Much?” Chicago, IL. March 30, 2012.
Organizer and Chair, Southern Regional Conference on Statistics (SRCOS). “Novel Dose Finding Designs in Clinical Trials.
Jekyll Island, GA. June 4-6, 2012.
Organizer, “Early Phase Adaptive Trial Designs Workshop.” Charleston, SC. October 2014
EXTERNAL DATA SAFETY AND MONITORING COMMITTEES
2010 – 2012 Member, TaiMed Biologics DSMB member for A Phase 1, Randomized, Double-Blinded, Placebo-
Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers
2009 – present Member, Pan American Cancer Trials Network's Data and Safety Monitoring Board.
2010 – present Member, Obesity & Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty
Acids DSMB (Mayo Clinic)
2010 – present Member, NHLBI Blood and Marrow Transplant Clinical Trials Network, Data Safety and
Monitoring Board, Panel 2
ELIZABETH GARRETT-MAYER PAGE 4 OF 31 MAY 16
2010 – present Member, AIDS Malignancies Consortium, Data Safety and Monitoring Board
2014 – present Member, ANCHOR (Anal Cancer/HSIL Outcomes Research Study) Data Safety and Monitory Board
2015 – present Member, A Phase I/II Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of XXX in
Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer, Data
Safety and Monitoring Board.
EXTRAMURAL GRANTS/AWARD AMOUNT (CURRENT AND PAST): CURRENT RESEARCH SUPPORT 1P01CA186866-01A1 (NIH/NCI) PI: Li, Zihai 07/01/2015 – 06/30/2020
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
Role: Core Co-Leader
R01DA021619-05 (NIH/NIDA) PI: Carpenter 09/15/2013 – 05/31/2018
Brief, Novel Smoking Cessation in Primary Care: A Comparative Effectiveness Trial
Role: Co-Investigator
1 R01 NR012432-01A1(NIH/NINR) PI: Spruill 04/01/2012 - 01/31/2016
Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs
Role: Co-Investigator
2P30 CA138313-01 (NIH/NCI) PI: Alberg/Garrett-Mayer 04/01/2008 – 03/31/2018
Medical University of South Carolina – Cancer Center Support Grant, Biostatistics Core
Role: Principal Investigator of Biostatistics Shared Resource R01CA154992-01 (NIH/NCI) PI: Carpenter 12/01/2010 – 3/31/2016
A Novel Trial of Smokeless Tobacco for Cessation Induction in Unmotivated Smokers Role: Co-Investigator 1 P01 CA154778-01A1 (Loyola/NIH/NCI) PI: Nishimura/Garrett-Mayer 09/01/2011 – 08/31/2016
TCR Gene Modified T Cells for Adoptive Immunotherapy
Role: Principal Investigator of Biostatistics Core 1 K12CA157688-01A1 (NIH/NCI) PI: Lilly 04/01/2013 – 03/31/2018
MUSC/HCC Paul Calabresi Clinical and Translational Oncology Training Program
Role: Co-Investigator R21CA194469-01 (NIH/NCI) PI: Turner 05/06/2015 – 04/30/2016 (PQ3) Ages and Race Specific Tumor Immune Response in Prostate Cancer Role: Co-Investigator COMPLETED RESEARCH SUPPORT
VA Merit Award PI: Gattoni-Celli 01/01/2010 - 12/31/2015
Vitamin D Supplementation in Veterans with Early-Stage Prostate Cancer: A Randomized Study
Role: Co-Investigator
R21CA158530 (NIH/NCI) PI: Reed 09/01/2012 – 08/31/2014
RCT of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients
Role: Co-Investigator
Leidos Biomedical Research, Inc. PI: Garrett-Mayer 04/24/2012 – 09/30/2014
Biostatistical Services Supporting the NCI's US-Latin America Clinical Research Network (US-LACRN)
Department of Defense W811XWH-09-1-0300 PI: Kraft 05/01/2009 – 04/30/2013
The Mechanism of Action of Unique Small Molecules that Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth
Role: Co-Investigator
R01 CA127905 (NIH/NCI) PI: Moussa 05/01/09 – 03/31/14
ELIZABETH GARRETT-MAYER PAGE 5 OF 31 MAY 16
Thromboxane Beta Receptors in Human Bladder Cancers
Role: Co-Investigator
2 P01 CA097132-06 (NIH/NCI) PI: Ogretmen/Hannun 08/01/08 - 7/31/13
Sphingolipids in Cancer Biology and Therapy: Project 4-Regulation of ER Stress by de Novo Ceramide Synthesis in Head and Neck
Cancer
Role: Co-Investigator
5 R01 FD003542-02 PI: Frankel 09/01/2009 – 08/21/2012
A Phase I/II Study of Intraventricular DepoCyt (Orphan Drug Designation 06-2348) in Patients with Recurrent Glioblastoma
Role: Co-Investigator
R01 CA142362-02 (NIH/NCI) PI: Parsons 01/01/10 – 12/31/12
Regulation of the Tumor Microenvironment by KSHV
Role: Co-Investigator
K23 DA020482 (NIH/NIDA) PI: Carpenter 09/30/07-08/31/11
Stimulus Control and Trajectories of Adolescent Smoking
Role: Co-Investigator
Genentech AVF44815 PI: Thomas 02/10/09 – 03/11/12
A Randomized Open-Lable Multi-Institutional Phase II study of the Combination of Bevacizumab and Erlotinib Compared to
Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)
Role: Co-Investigator
2R44CA126461-02 (NIH/NCI) Subaward PI: Nishimura 06/01/2010 - 07/31/2011
Clinical Vector for TCR Immunotherapy Targeted to Melanoma
Role: Co-Investigator
5 P01 CA078582 (NIH/NCI) PI: Watson 09/30/08 - 04/30/10
Role of Ets Genes in Transformation and Differentiation
Role: Co-Investigator 1R03CA137826-01A1 (NIH/NCI) PI: Cunningham 07/01/09 – 06/30/11 Age-Specific and Age-Standardized Breast Cancer Subtype Incidence and Disparities Role: Co-Investigator
SECTR grant (state funded) PI: Voelkel-Johnson 10/01/08 – 9/30/09
Use of Exfoliated Cells in Urine for Detection of Cancer and Prediction of Treatment susceptibility
Role: Co-Investigator
1RO3 CA128482-01 (NIH/NCI) PI: Carter 06/01/07 – 12/31/08
The Impact of Dragon Boat Racing on Cancer Survivorship
Role: Co-Investigator
RSG-07-004-01-CCE (American Cancer Society) PI: Emens 10/01/06 - 01/15/07
Manipulating Immunoregulatory Pathways to Maximize Breast cancer Vaccine Activity
Role: Co-investigator
0B2P50CA088843-06A1 (NIH/NCI) PI: Davidson/Parmigiani 09/30/06 - 01/15/07
1BBreast SPORE / Biostatistics Core
2BRole: Co-investigator
1R2CA123888-01 (NIH) PI: Altiok 07/01/06 - 01/15/07
Prediction and Assessment of Response to Targeted Therapy in Pancreatic Cancer
Role: Co-investigator
R01CA116554 (NIH/NCI) PI: Hidalgo 06/01/06 – 01/15/07
Individualized Treatment of Pancreatic Cancer
Role: Co-investigator
ELIZABETH GARRETT-MAYER PAGE 6 OF 31 MAY 16
1R21CA117125 (NIH/NCI) PI: Messersmith 06/01/06 – 01/15/07
Evaluation of Bay43-9006/Cetuximab in Colorectal Cancer
Role: Co-investigator
P30CA006973 (NIH/NCI) PI: Abeloff / Parmigiani 05/01/06 – 01/15/07
Regional Oncology Research Center: Bioinformatics
Role: Co-investigator
NCI/Avon Foundation Partnership for Progress PI: Wolff 01/01/06 – 01/15/07
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Treatment of Metastatic Breast Cancer.
Role: Co-investigator
TAX 2501 (Aventis) PI: Eisenberger 10/01/05 – 01/15/07
Prostate Cancer Taxotere Study
Role: Co-investigator
R21CA109283 (NIH/NCI) PI: Hidalgo 07/01/05 – 01/15/07
Pharmacogenomics of Erlotnib
Role: Co-investigator
R21CA112919 (NIH/NCI) PI: Hidalgo 09/17/04 – 01/15/07
Pharmacodynamic-Guided Dose-Finding Study of Rapamycin in Adult Patients with
Solid Tumors
Role: Co-investigator
DMS0342111 (National Science Foundation) PI: Parmigiani 05/01/04 – 04/30/06
Multi-Study Genomic Data Analysis
Role: Co-investigator
R21CA108774 (NIH) PI: Levitsky 12/30/03 – 11/30/05
Cancer Vaccines in the Treatment of CML
Role: Co-investigator
304-2294 PI: Stearns 10/01/03 – 09/30/05
(Translational Breast Cancer Research Consortium)
The Contralateral Breast as a Model for Chemoprevention: Preliminary Evaluation of Factors of Sensitivity of Resistance to
Anastrozole
Role: Co-investigator
310-2011 (Aventis) PI: Garrett-Mayer 09/01/03 – 01/15/07
A Multicenter, Open-Label Phase II Trial of Adjuvant Taxotere in Patients with High
Risk of Relapse Following Prostatectomy
Role: Co-investigator
P30CA006973 (NIH/NCI) PI: Abeloff/Wolff 05/15/03 – 01/15/07
Regional Oncology Research Center: Phase I Study of Doxcetaxel/ST 1571 in Breast Cancer
Role: Co-investigator
R21CA957030-01A1 (NIH) PI: Zeiger 05/01/03 – 04/30/05
Microarray Analysis of Thyroid Neoplasms
Role: Co-investigator
P01CA 098252 (NIH) PI: Wu/Wang 12/01/02 – 11/30/03
SPORE in Cervical Cancer
Role: Co-investigator
P50CA096784 (NIH) PI: Sidransky/Goodman 10/01/02 – 9/30/04
SPORE in Head and Neck Cancers
ELIZABETH GARRETT-MAYER PAGE 7 OF 31 MAY 16
Role: Co-investigator
P50CA096888 (NIH) PI: Ambinder/Piantadosi 09/01/02 – 01/15/07
SPORE in Lymphoma Cancer
Role: Co-investigator
PAR-99-128 (NIH/NCI) PI: Newschaffer 07/01/02 – 08/14/02
Serum FAS and the Early Detection of Breast Cancer
Role: Co-investigator
P01CA070970 (NIH/NCI) PI: Civin/Piantadosi 04/01/02 – 01/15/07
Hematopoietic Stem Cells for Transplantation
Role: Co-investigator
PA-00-047 (NIH) PI: Flinn 01/01/02 – 12/31/03
Augmenting ADCC with Rituximab and LAK Cells
Role: Co-investigator
P30CA006973 (NIH/NCI) PI: Abeloff /Piantadosi 07/13/01 – 01/15/07
Regional Oncology Research Center: Biostatistics
Role: Co-investigator
TURPG-00-294-01-PBP (American Cancer Soc.) PI: Shankar 07/01/01 – 06/30/04
Fruits and Vegetables Intervention in DC Public Housing
Role: Co-investigator
5P30 CA06973-39S2 (NIH/NCI) PI: Zabora 05/01/01 – 04/30/02
Regional Oncology Research Center – A Program for Depression Among African American Cancer Survivors
Role: Co-investigator
DK-00-002 (NIDDK) PI: Germino 09/30/00 – 09/29/03
The Hopkins DK Center for the Analysis of Gene Expression
Role: Co-investigator
P50CA88843 (NIH/NCI) PI: Davidson/Parmigiani 09/01/00 – 09/29/06
Breast SPORE / Biostatistics Core
Role: Co-investigator
R03 CA88769-02 (NIH/NCI) PI: Zabora 08/23/00 – 06/30/02
Family Dynamics and Problem-Solving Education for Caregivers
Role: Co-investigator
R01 A141956-02 (NIH) PI: Semba 09/01/99 – 08/31/03
Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS
Role: Co-investigator
R01-HD32247 (NIH) PI: Semba 08/15/99 – 07/31/02
Micronutrients and Mother-to-Child Transmission of HIV
Role: Co-investigator
R01-MH56639 (NIMH) PI: Zeger 08/15/97 – 07/31/03
Statistics for Longitudinal Studies of Mental Health Services
Role: Co-investigator
5M01 RR0035-32 (NIH) PI: Saudek 12/01/96 – 11/30/02
General Clinical Research Center (GCRC)
Role: Co-investigator
T32-MH19901 (NIH/NIMH) PI: Liang 07/01/93 – 06/30/03
ELIZABETH GARRETT-MAYER PAGE 8 OF 31 MAY 16
Biostatistics Mental Health Psychiatry Training Program
Role: Trainee
N01-AG12122 (NIH/NIA) PI: Fried 07/01/91 – 02/28/01
Women’s Health and Aging Study
Role: Research Assistant
AWARDS, HONORS, MEMBERSHIP IN HONORARY SOCIETIES:
1994 Phi Beta Kappa, Bowdoin College Chapter
1994 Summa cum laude, Bowdoin College
1995-1999 Biostatistics Mental Health/Psychiatry Training Grant
1998 Helen Abbey Award for Excellence in Student Teaching
2000 – present Delta Omega Society
2006 – present Associate Editor, Clinical Trials
2010 Hollings Cancer Center Cancer Prevention and Control Collaborative Paper Award
2014 Outstanding Mentor Award, Department of Public Health Sciences.
2016 MUSC Foundation Teaching Excellence Award Nominee
ACADEMIC COMMITTEE ACTIVITIES:
MUSC
2007 – 2008 Oncology Biostatistics Search Committee, Hollings Cancer Center and Department of Biostatistics & Epidemiology
2007 – 2009 Student Recruiting Committee , Department of Biostatistics & Epidemiology
2007 – 2009 Faculty Awards Committee , Department of Biostatistics & Epidemiology
2007 – 2009 Advanced Exam Committee, Department of Biostatistics & Epidemiology
2007 – 2009 Seminar Committee , Department of Biostatistics and Epidemiology
2007 – present Protocol Review Committee, Hollings Cancer Center
2007 – 2014 Co-chair, Data Safety Monitoring Committee, Hollings Cancer Center
2007 – present Member, Data Safety Monitoring Committee, Hollings Cancer Center
2007 – 2010 Executive Council, Hollings Cancer Center
2009 – 2011 Co-Director, Graduate Training Program, Biostatistics & Epidemiology, Department of Medicine
2009 – 2013 Senior Search Committee, Biostatistics & Epidemiology, Department of Medicine
2010 – present Medical Scientist Training Program (MD/PhDAdmissions Committee, College of Medicine
2011 Judge, Student Research Day, College of Graduate Studies
2011 – 2015 Chair, Admissions Committee, Department of Public Heath Sciences
2012 – 2014 Member, Search Committee for Dean of College of Graduate Studies
2013 – 2014 Member, Search Committee for Bioinformatics Candidates, Center for Genomics
2014 – present Member, Biostatistics Curriculum Committee, Department of Public Health Sciences
2015 – present Chair, Biostatistics Curriculum Committee, Department of Public Health Sciences
2015 – present Member, Masters of Public Health Program Committee, Department of Public Health Sciences
Johns Hopkins University
1999-2001 General Clinical Research Center, School of Medicine
2000-2005 Expressionist Working Group member, Schools of Medicine and Public Health
2000-2006 Oncology Scientific Clinical Review Committee, Sidney Kimmel Comprehensive Cancer Center
2004 Bioinformatics Faculty Search Committee, Departments of Oncology and Biostatistics
2004-2005 Co-Chair, Oncology Scientific Clinical Review Committee, Sidney Kimmel Comprehensive
Cancer Center
2006-2007 Chair, Oncology Clinical Research Review Committee, Sidney Kimmel Comprehensive Cancer
Center
2005-2007 Organizer, Cancer Clinical Trials Working Group, Sidney Kimmel Comprehensive Cancer Center
MAJOR TEACHING RESPONSIBILITIES:
COURSES TAUGHT:
MUSC
ELIZABETH GARRETT-MAYER PAGE 9 OF 31 MAY 16
Analysis of Survival Data 2008 Instructor (3 credit hours)
Department of Biostatistics, Bioinformatics, and Epidemiology
This is a one-semester introductory course in theory and application of analytic methods for time-to-event data. The methods covered
include nonparametric, parametric, and semi-parametric (Cox model) approaches. The topics covered will also include types of
censoring and truncation, sample size and power estimation, and a brief introduction to counting process method.
Biostatistical Methods II: Regression 2009-2010 Instructor (4 credit hours)
This is a one-semester course intended for graduate students pursuing degrees in biostatistics and related fields such as epidemiology
and bioinformatics. Topics covered will include linear, logistic, poisson, and Cox regression. Advanced topics will be included, such
as ridge regression or hierarchical linear regression if time permits. Estimation, interpretation, and diagnostic approaches will be
discussed. Software instruction will be provided in class in R and Stata.
Computing for Research I 2011-2014 Instructor (3 credit hours)
Students learn to use the primary statistical software packages for data manipulation and analysis, including (but not limited to): R, R
Bioconductor, SAS, SAS macro, and Stata. Additionally, students will learn: how to use the division's high speed cluster-computing
environment, how to practice the principles of reproducible research using Sweave in R, and how to use LaTeX and BibTeX for
manuscript and presentation development. This is a three credit course.
Introduction to Biostatistics: Methods I 2015 Instructor (4 credit hours)
This course introduces basic applied descriptive and inferential statistics. Topics include elementary probability concepts, an
introduction to statistical distributions, point and interval estimation, hypothesis testing, and simple linear regression and correlation.
Basic data management and analysis techniques will be introduced using computing software in a 1 hour computer lab session each
week.
Johns Hopkins University
Methods in Clinical Research 1991-2001 Instructor
The Johns Hopkins University School of Medicine. Two-week intensive course taught primarily to medical fellows and junior
faculty. Dr. Garrett-Mayer’s instruction included daily hour-long lectures using statistical software.
Statistical Reasoning in Public Health I & II 2000-2001 Instructor
Summer Epidemiology Institute, Johns Hopkins School of Hygiene and Public Health. Two-week intensive course taught to graduate
students. Dr. Garrett-Mayer’s instruction included daily 4 hour-long lectures and instructional labs on introductory biostatistics.
Statistics for Psychosocial Research: 2000-2004, 2006 Co-Instructor
Measurement and Structural Equation Models
The Johns Hopkins University Bloomberg School of Public Health. One semester (16 weeks). Dr. Garrett-Mayer has co-instructed
this course for five years with Dr. Richard Miech from the Department of Mental Health in the School of Public Health. Course
consists of three hours of lectures and one hour-and-a-half computer laboratory seesion per week. Nominated for “Golden Apple”
teaching award in 2000-2001 academic year.
Repeated Multi-Item Reponses in Clinical Trials 2001 Instructor
Biometrics Department, Ortho-McNeil Pharmaceuticals, Raritan, New Jersey. One-day short course. Conducted with three other
faculty from the Biostatistics Department at the School of Public Health. Dr. Garrett-Mayer’s component consisted of a two-hour
lecture on using latent class modeling for assessing treatment effects.
The Psychiatry Research Lecture Series 2001 Instructor
Psychiatry Research Center, Kennedy Krieger Institute, Baltimore, MD. Six-lecture series in basic statistical methods. One-hour
lectures given to psychiatrists and other faculty in psychiatric research from the Kennedy Krieger Institute.
Clinical Trials in 20 Hours 2002 Co-Instructor
Sidney Kimmel Cancer Center, Johns Hopkins University. Co-taught with four other faculty of the Oncology Center’s Division of
Clinical Trials and Biometry. Course consists of 20 one-hour lectures on statistical topics relevant to clinical trial design, conduct, and
analysis.
ST. GEORGE’S UNIVERSITY SCHOOL OF MEDICINE
ELIZABETH GARRETT-MAYER PAGE 10 OF 31 MAY 16
Biostatistics 2004 Instructor
St. George’s University School of Medicine, St. George, Grenada. Two-week intensive course taught to second-year medical students
in January and again in May. Dr. Garrett-Mayer’s instruction included daily two hour-long lectures biostatistics in medical research
and daily office hours.
MENTORING (PRE- AND POST-DOCTORAL)
MENTORING FROM 2000-2006 OCCURRED AT JOHNS HOPKINS UNIVERSITY.
MENTORING FROM 2007-PRESENT OCCURRED AT MEDICAL UNIVERSITY OF SOUTH CAROLINA
ADVISEES (AS PRIMARY ADVISOR)
2004-2008 Shu-Chih Su PhD, Biostatistics
2004 Naomi Ko MPH, Biostatistics
2004-2006 Lei Zhang ScM, Biostatistics
2005-2006 Yi-Chun Ou Yang ScM, Biostatistics
2007-2009 Emily Van Meter MS, Biostatistics
2007-2009 Chengwu Yang PhD, Biostatistics
2009-2010 Emily Van Meter PhD, Biostatistics
2011-2014 Codruta Chiuzan PhD, Biostatistics
2013-present Wei Wei PhD, Biostatistics
2014-present Nathaniel O’Connell PhD, Biostatistics
THESIS COMMITTEES
UNAME U UTITLE U UDEFENSE DATE U
Thomas Travison PhD, Biostatistics March 2002
Chiung-Yu Huang PhD, Biostatistics March 2002
Chuan-Yu Chen PhD, Mental Health January 2003
Yingyao Hu PhD, Economics (A&S) March 2003
Kathleen Hayden PhD, Mental Health August 2003
Wesley Eddings PhD, Biostatistics December 2003
Claire Lucas PhD, Health Policy &Mgmt December 2003
Kerry Pisacane PhD, Health Policy & Mgmt March 2004
Ya-Fen Chan PhD, Mental Health March 2004
Judith Bass PhD, Mental Health July 2004
Kathleen Cardona PhD, Population & Family Health Sciences March 2005
Christine Koth PhD, Mental Health August 2005
Michelle Kittleson PhD, Clinical Investigation (SOM) December 2005
Hong-fei Guo PhD, Biostatistics March 2006
Wei Hua PhD, International Health August 2006
Chengwu Yang PhD, Biostatistics August 2009
Jill Nonemaker MS, Epidemiology April 2008
Emily Van Meter PhD, Biostatistics August 2010
Jill Nonemaker MS, Epidemiology July 2007
James Whittle MSCR
Lee Wheless MSCR December 2008
Keisuke Shirai MSCR April 2009
Lee Wheless PhD, Epidemiology June 2012
Sarah Logan PhD, Epidemiology July 2013
Jessica Thaxton MSCR July 2014
Alice Mims MSCR July 2015
Rachel Moss Carroll PhD, Biostatistics November 2015
Melanie Jefferson PhD, Health & Rehabilitation Science April 2016
Matthew Hale PhD, Marine Science
David Neskey MSCR April 2016
THESIS PROPOSAL ORAL EXAM COMMITTEES
UNAME U UTITLE U UDEFENSE DATE
ELIZABETH GARRETT-MAYER PAGE 11 OF 31 MAY 16
Hong-fei Guo PhD, Biostatistics November 2001
Laura Pritchett PhD, Population & Family Health Sciences February 2002
Kathleen Hayden PhD, Mental Health November 2002
Michelle Shardell PhD, Biostatistics December 2002
Dongmei Liu PhD, Biostatistics December 2002
Xianghua Luo PhD, Biostatistics January 2003
Kerry Pisacane PhD, Health Policy & Management February 2003
David Cohen PhD, Biostatistics February 2003
Judith Bass PhD, Mental Health September 2003
Andrea Stone PhD, Mental Health March 2003
Ya-Fen Chan PhD, Mental Health March 2003
Yi Huang PhD, Biostatistics April 2003
Yandong Qiang PhD, International Health April 2003
Ting Wing PhD, Epidemiology May 2003
Jose Arbelaez PhD, Epidemiology May 2003
Jeanhee Hong PhD, Health Policy & Management June 2003
Wei Hua PhD, International Health July 2003
Michelle Chervak PhD, Health Policy & Management August 2003
Stephanie Smith PhD, Health Policy & Management August 2003
Christine Koth PhD, Mental Health September 2003
Brian Egleston PhD, Biostatistics November 2003
Erin Winstanley PhD, PhD, Mental Hygiene December 2003
Alyson Hall PhD, Health Policy & Management December 2003
Gwendolyn Bergen PhD, Health Policy & Management February 2004
Melissa Davey PhD, Mental Health June 2004
Michelle Kittelson PhD, GTPCI June 2004
Celeste Torio PhD, Health Policy & Management June 2004
Regina Shih PhD, Mental Health September 2004
Joseph Logan PhD, Health Policy & Management November 2004
Rajeeve Ramchand PhD, Mental Health December 2004
Robert Scharpf PhD, Biostatistics December 2004
Richard Skolasky PhD, Health Policy & Management February 2005
Shu-Chih Su PhD, Biostatistics October 2005
Amanda Kalaydjian PhD, Mental Health November 2005
Jessica Langbaum PhD, Mental Health January 2006
Haejoo Chung PhD, Health Policy & Management February 2006
Barbara Biedrzycki PhD, Nursing (SON) March 2006
Eva Bazant PhD, Population & Family Health Sciences May 2006
TRAINING GRANT PARTICIPATION
K23, Sean Berenholtz (Anesthesia and Critical Care Medicine, Johns Hopkins University)
K23, Wells Messersmith (Oncology, Johns Hopkins University)
K01, Hexin Chen (Oncology, Johns Hopkins University)
K23, Matthew Carpenter (Psychiatry and Cancer, Medical University of South Carolina)
Department of Defense Prostate Cancer Training Award. Thomas Beckham (PC101962) lab of James Norris). “Evaluation of
Acid Ceramidase Overexpression-Induced Activation of the Oncogenic Akt Pathway in Prostate Cancer.
K08, Co-Mentor for Yubin Kang (Division of Hematology/Oncology, Dept. of Medicine, MUSC). “Plerixafor for allogeneic
hematopoietic stem cell transplantation”
ACS Career Development Award, Katherine Sterba (Division of Biostatistics and Epidemiology, MUSC).
Conquer Cancer Foundation (ASCO) Career Development Award for Yubin Kang. (Division of Hematology/Oncology, Dept.
of Medicine, MUSC). A phase I/II study: enhancing donor cell recovery with CXCR4 antagonists
in hematopoietic cell transplantation
NCI K12 Paul Calabresi Career Development for Clinical & Translational Oncology Program Award
LECTURES AND PRESENTATIONS
MEETINGS/CONFERENCES/WORKSHOPS
AACR Cancer Biostatistics Workshop: Developing Targeted Agents
ELIZABETH GARRETT-MAYER PAGE 12 OF 31 MAY 16
Research Workshop, Sonoma, CA. July 2008 Instructor
A one-week intensive workshop in statistical methods in oncology and collaborative interactions between biostatisticians and
oncologists for entry-level to mid-level biostatisticians in the cancer field. Dr. Garrett-Mayer’s role is as a consulting
statisticians including daily group and one-on-one meetings with students, and informal teaching sessions. Dr. Garrett-Mayer
also gives a one-hour lecture on Phase II clinical trials in oncology.
AACR/ASCO Methods in Clinical Cancer Research Workshop,Vail, CO.
August 2002-2007, 2011-2015 Instructor
August 2008-2010, Course Director & Instructor
One-week intensive course for post-doctoral fellows and junior faculty in oncology. Dr. Garrett-Mayer’s role is as consulting
statistician, including daily group and one-on-one meetings with students, and informal teaching sessions. Dr. Garrett-Mayer
also gives didactic lectures: Novel Phase II Clinical Trials and Statistical Considerations: From Hypothesis to Analytic Plan.
Systematic Analysis of Research Risks Workshop Retreat in Queenstown, MD January 11-13, 2009
The goal of this workshop is to develop and apply a method for categorizing and evaluating the risks of research procedures.
For this purpose, workshop discussions will aim 1) to delineate more fine-grained categories of research risk than currently
exist; 2) to specify important normative and practical implications of these risk categories (e.g. whether consent must be
required); 3) to determine how these categories of risk map on to existing risk classifications in current research regulations;
and 4) to reach consensus on which risk category common research interventions should be placed based on the available
empirical data about the risks they pose. The project will focus on research that has social value, but offers no prospect of
direct benefit to individual study participants.
ASCO-AACI Workshop on Best Practices in Cancer Clinical Trials in Alexandria, VA March 8, 2016
The overarching goal of the initiative is to promote practical solutions to meeting existing regulatory and administrative
requirements on research. Other project elements include the following: (1) Stakeholder Survey: The working group is
overseeing a survey of trial administrators, investigators, and research staff to identify the most pressing issues in cancer
clinical trials that could be addressed by the initiative and to gather data on use of existing tools. (2) Proceedings of the
Workshop: The working group will write a manuscript that summarizes the discussion and recommendations from the
workshop and publish it as a Special Article in the Journal of Clinical Oncology. (3) Dissemination: ASCO will use the 2016
ASCO Annual Meeting to highlight project findings. It will also develop practical resources and toolkits to aid in the
implementation of the best practices identified by the working group.
INTRAMURAL LECTURES AND PRESENTATIONS
Lecture Series for Hematology/Oncology Fellows, Pediatric Oncology Fellows and Radiation Oncology Residents on
Methods in Clinical Cancer Research. 8 lectures per term, given semi-annually. Spring 2012 & Spring 2014
Graphical Display of Data and Statistics for Basic Science Researchers. Apple Tree Educational Series Lecture. April 21,
2014.
INVITED TALKS
An Introduction to Biostatistics and Some New Findings on the Effects of Complications in a Surgical Population. Bowdoin
Science Symposium, Brunswick, Maine, October 1997.
Methods for Determining the Number of Categories of Functional Disability. The Gerontological Society of America Annual
Meeting, Philadelphia, PA. November 23, 1998
Defining Major Depression Via Latent Class Model Diagnosis. Biostatistics Grand Rounds, The Johns Hopkins University
Bloomberg School of Public Health, Baltimore, MD. December 3, 1999.
Methods for Evaluating a Latent Class Model for Depression. Eastern North American Region (ENAR) International
Biometrics Society Annual Meeting, Chicago, NC. March 26, 2000.
Assessing Estimability of Latent Class Models Using a Bayesian Estimation Approach. Eastern North American Region
(ENAR) International Biometrics Society Annual Meeting,Charlotte, NC. March 26, 2001.
ELIZABETH GARRETT-MAYER PAGE 13 OF 31 MAY 16
Latent Class Model Graphical Diagnostic Tools Using An MCMC Estimation Procedure. Society for Prevention Research
Annual Meeting, Seattle, WA. June 1, 2002.
A Statistical Framework for Expression-Based Molecular Classification. Joint Statistical Meetings of the American Statistical
Association, New York, NY. August 12, 2002.
Methods for Evaluating the Performance of Diagnostic Tests in the Absence of a “Gold-Standard:” A Latent Class Model
Approach. Brown University Seminar Series, Brown University Division of Biostatistics. Providence, RI.
December 9, 2002.
Statistical Issues in the Analysis of Patient Outcomes. Guest lecture in ‘Patient Outcomes and Quality of Health Care.’
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health. April 2003.
Statistical Issues in Clinical Studies Using Laboratory Endpoints. American College of Surgeons Oncology Group Meeting,
Montreal, Canada. June 5, 2003. College of Surgeons Canada.
Methods for Evaluating the Performance of Diagnostic Tests in the Absence of a “Gold-Standard:” A Latent Class Model
Approach. CARMA Institute, Virginia Commonwealth University. March 5, 2004.
A Nested Unsupervised Approach to Identifying Novel Molecular Subtypes. 2nd Institute of Mathematics and International
Society for Bayesian Analysis, Joint Meeting, Bormio, Italy. January 12, 2005.
A Likelihood Based Approach fro Early Stopping in Phase II Cancer Clinical Trials. Society for Clinical Trials Annual
Meeting. Orlando, FL. May 21, 2006.
Protocol Development and Study Design. Patient Advocate Training Workshop Understanding Process: Supporting Change
to Improve Cooperative Group Research. Baltimore, MD. November 6, 2006.
A Likelihood Based Approach for Early Stopping in Phase II Cancer Clinical Trials. GlaxoSmithKline, Collegeville, PA.
December 2006.
A Likelihood Based Approach for Early Stopping in Phase II Cancer Clinical Trials. Eastern North American Region,
International Biometric Society. Atlanta, GA. March 14, 2007.
Putting the Novelty Back in Phase II Studies. AACR/ASCO Methods in Clinical Cancer Research Workshop. Vail, CO.
Aug 2007 and Aug 2008.
Efficient Likelihood Based Approaches for Phase II Cancer Clinical Trials. Memorial Sloan Kettering Cancer Center
Seminar Series, New York, NY. May 14, 2008.
The Continual Reasssessment Method. NCI/CTEP Investigational Drug Phase I Trial Design Conference. Rockville, MD.
July 8, 2008.
Overview of Standard Phase II Design Issues. Cancer Biostatistics Workshop: Developing Targeted Agents. Sonoma, CA.
July 13-19, 2008.
Statistical Considerations in Protocol Development: From Hypothesis to Analysis. Methods in Clinical Cancer Workshop.
Vail, CO. Aug 2009.
Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Johns Hopkins University. Baltimore, MD. June 23,
2009.
The CRM for ordinal and multivariate outcomes. CRM Workshop. Memorial Sloan Kettering Cancer Center. New York,
NY. October 2, 2009.
The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs. South Carolina
Chapter of The American Statistical Association Annual Meeting. Charleston, SC. December 4, 2009.
ELIZABETH GARRETT-MAYER PAGE 14 OF 31 MAY 16
Novel Trial Designs for Early Phase Drug Development. CNIO Frontiers Meeting "Molecular Cancer
Therapeutics". Madrid, Spain. March 8-10, 2010.
Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Quantitative Science Seminar Series. Vanderbilt
University, Nashville, TN. April 9, 2010.
Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Society for Clinical Trials Annual Meeting, Invited
Session. Baltimore, MD. May 17, 2010.
Frequentist, Bayesian and Likelihood Designs for a Phase II Cancer Trial with a Time-to-Event Endpoint:
Head to Head Comparison of Three Philosophies of Trial Design. Invited Session. Vancouver, BC. May 17, 2011.
Biostatistical Aspects of Rational Clinical Trial Designs, Workshop on Pancreatic Cancer. The Banbury Center, Coldspring
Harbor, NY. June 21, 2011.
Dose finding designs driven by immunotherapy outcomes. 2nd CRM Workshop. University of Paris, Paris, France.
September 15-16, 2011.
Incorporating Early Stopping Rules in Phase II Studies. American Association of Cancer Research Annual Meeting.
Chicago, IL. March 31, 2012.
Dose finding designs driven by immunotherapy outcomes with application to a metastatic melanoma phase I trial. Southern
Regional Council on Statistics Annual Meeting. Jekyll Island, GA. June 4-6, 2012.
Adaptive phase I design for immunologic outcomes with safety constraints in cancer immunotherapy clinical trials. Joint
Statistical Meetings of the American Statistical Association. Montreal, Canada. August 5, 2013.
Clinical trial endpoints: selection, analysis and interpretation. San Antonio Breast Cancer Symposium - Cancer Therapy and
Research Center at UT Health Science Center. San Antonio, TX. Dec10-14, 2013
Likelihoood Approaches for Trial Designs in Early Phase Oncology Clinical Trials. Seminar Series, Columbia University
Department of Biostatistics. New York City, NY. April 24, 2014.
New Challenges: Model-based Dose Finding in the Era of Targeted Agents. Symposium on Early Phase Dose Finding
Methodology. Universite Paris VI. Paris, France, April 15, 2015.
Large Phase I Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives; Panel Discussion.
Accelerating Anticancer Agent Development and Validation Workshop. Bethesda, MD. May 7, 2015.
Statistical Considerations for Large First-in-Human Trials. Expansion Cohorts Mini-Symposium. Office of Hematology &
Oncology Products. United States Food and Drug Administration. Silver Spring, MD. September 10, 2015
The Changing Landscape of Phase I Trials in Cancer: A Novel Designs for Immunotherapies in Cancer. The Division of
Biomedical Statistics and Informatics. The Mayo Clinic. Rochester, Minnesota. October 2, 2015
Statistical Considerations for Large Expansion Cohorts. Friends of Cancer/Center for Health Policy at Brookings Annual
Meeting. Washington, DC. November 17, 2015.
The Changing Face of Early Phase Studies in Oncology Therapeutics: Tensions in a New Era of Immunotherapies.
Department of Biostatistics. St Jude’s Children Research Hospital. Memphis, TN. Feb 26, 2016
Statistical Issues in Cancer Clinical Trials: Designing Your Trial for Success. Accelerating Anti-Cancer Agents
Development and Validation: Fundamentals Workshop. Bethesda, MD. May 2, 2016
OTHER ACADEMIC PROFESSIONAL ACTIVITIES
Ad hoc Advisory Committee, Mock Site Visit. University of Texas San Antonio Cancer Therapy and Research Center.
December 19, 2013.
EXTRAMURAL PROFESSIONAL ACTIVITIES:
ELIZABETH GARRETT-MAYER PAGE 15 OF 31 MAY 16
CONSULTANTSHIPS
1999-2001 General Clinical Research Center, Johns Hopkins University
2002-2006 Department of Clinical Bioethics, National Institutes of Health
2004, 2008-9 Bingham McCutchen LLP
2015 - 2016 Tactical Therapeutics
2015 – 2016 Okava Pharmasceuticals
PUBLICATIONS:
UPEER REVIEWED JOURNAL ARTICLESU: EL
Electronic access to journal articles is available by clicking on the links below, or by visiting My NCBI Bibliography .
1. Pronovost P, Jenckes MW, Dorman T, Garrett E, Breslow MJ, Rosenfeld BA, Lipsett PA, Bass E. Organizational
characteristics of intensive care units related to outcomes of abdominal aortic surgery. Journal of the American Medical
Association. 1999; 281:1310-1317. PMID: 10208147
2. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65. American
Journal of Epidemiology. 1999; 149:794-800. PMID: 10221315
3. Pronovost PJ, Dorman T, Sadnivokoff N, Garrett E, Breslow MJ, Rosenfeld BA. The association between preoperative
patient characteristics and both clinical and economic outcomes after abdominal aortic surgery. Journal of Cardiothoracic
and Vascular Anesthesiology. 1999; 13:549-554. PMID: 10527223
4. Ahn NU, Sponseller PD, Ahn UM, Nallamshetty L, Rose PS, Buchowski JM, Garrett ES, Kuszyk BS, Fishman EK, and
Zinreich SJ. Dural ectasia in the marfan syndrome: mr and ct findings and criteria. Genetics in Medicine. 2000; 2 (3):173-
179. PMID: 11256662
5. Ahn UM, Ahn NU, Buchowski J, Garrett ES, Seiber A, Kostuik JP. Cauda equina syndrome secondary to lumbar disc
herniation: a meta-analysis of surgical outcomes. Spine. 2000; 25 (12):1515-1522. PMID: 10851100
6. Chaves PHM, Garrett ES, Fried LP. Screening for risk of mobility disability in the clinical setting: predictive nomograms
for older women. Archives of Internal Medicine. 2000; 160 (6):2525-2533. PMID: 10979066
7. Semba R, Garrett ES, Johnson B, Guralnik JM, Fried LP. Hypovitaminosis D Among women with and without disability.
American Journal of Clinical Nutrition. 2000; 72 (6):1529-1534. PMID: 11101482
8. Garrett ES, Zeger SL. Latent class model diagnosis. Biometrics. 2000; 56 (4):1055-1067. PMID: 11129461
9. Ling SM, Fried LP, Garrett ES, Hirsch R, Guralnik JM, Hochberg MC, and the Women’s Health and Aging
Collaborative Research Group. The Accuracy of Self-Report of Physician Diagnosed Rheumatoid Arthritis in Moderately
to Severely Disabled Older Women. Journal of Rheumatology, 2000; 27(6): 1390-1394. PMID: 10852259
10. Ahn NU, Ahn UM, Nallamshetty L, Rose PS, Buchowski JM, Garrett ES, Kebaish, KM, Spononseller, PD. The lumbar
interpediculate distance is widened in adults with the marfan syndrome: data from 32 cases. Acta Orthopedica
Scandinavica. 2001; 72 (1); 67-71. PMID: 11327417
11. Hruban RH, Adsav NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G,
Longnecker DS, Luttges J, Offerhaus GJ. Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification
System for Pancreatic Duct Lesions. American Journal of Surgical Pathology. 2001; 25(5):579-586. PMID: 11342768
12. Huang W, Zeger SL, Anthony JC, Garrett ES. Latent variable model for joint analysis of multiple repeated and bivariate
time events. The Journal of the American Statistical Association. 2001; 96: 906-914.
13. Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. Anemia and interleukin-10, tumor necrosis
factor-a, and erythropoietin among children with acute, uncomplicated plasmodium falciparum malaria. Clinical and
Diagnostic Laboratory Immunology. 2001; 8:1164-1170. PMCID: PMC96244PMID: 11687458
ELIZABETH GARRETT-MAYER PAGE 16 OF 31 MAY 16
14. Semba RD, Kumwenda N, Taha TE, Mtimavalye L, Broadhead R, Garrett E. Impact of vitamin a supplementation on
anaemia and plasma erythropoietin concentrations in pregnant women: a controlled clinical trial. European Journal of
Haemotlogy. 2001; 66:389-395. PMID: 11488938
15. Melikian G, Mmiro F., Ndugwa C, Perry R, Jackson JB, Garrett E. Relation of Vitamin a and carotenoid status to growth
failure and mortality among ugandan infants with human immunodeficiency virus. Nutrition. 2001; 17 (7-8):567-572.
PMID: 11448574
16. Pronovost P, Garrett ES, Dorman T, Jenckes MW, Breslow M, Bass E. Variation in complications and opportunities for
improvement in quality of care of patients having abdominal aortic surgery. Langenbeck’s Archives of Surgery. 2002; 386
(4):249-256. PMID: 11466565
17. Pronovost PJ, Dang D, Dorman T, Lipsett PA, Garrett ES, Jenckes M. Intensive care unit nurse staffing associated with
increased risk of complications after abdominal aortic surgery. Effective Clinical Practice. 2001; 4(5): 199-206. PMID:
11685977
18. Levis M, Tse K-F, Smith BD, Garrett E, Small D. A flt3 tyrosine kinase inhibitor is selectively cytotoxic to aml blasts
harboring flt3/itd mutations (brief report). Blood. 2001; 98(3): 885-887. PMID: 11468194
19. Ahn NU, Ahn UM, Nallamshetty L, Springer BD, Buchowski JM, Funches L, Garrett ES, Kostuik JP, Kebaish KM,
Sponseller PD. Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes
after medical and surgical treatments. Journal of Spinal Disorders. 2001; 14(5):427-433. PMID: 11586143
20. Ahn NU, Nallamshetty L, Ahn UM, Buchowski JM, Rose PS, Garrett ES, Kebaish KM, Sponseller PD. Dural ectasia
and conventional radiography in the marfan lumbosacral spine. Skeletal Radiology. 2001; 30(6):67-71. PMID: 11465775
21. Munter P, Garrett E, Klag M, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the united states
population 25-74 years of age. Stroke. 2001; 33(5): 1209-1213. PMID: 11988592
22. Berenholtz SM, Pronovost PJ, Mullany D, Garrett E, Ness P, Dorman T, Klag M. Predictors of transfusion for spine
surgery in Maryland, 1997-2000. Transfusion. 2002; 42(4): 183-189. PMID: 11896333
23. Eichler FS, Itoh R, Barker PB, Mori S, Garrett ES, van Zijl P, Moser HW, Raymond GV. Proton mr spectroscopic and
diffusion tensor brain mr imaging in x-linked adrenoleukodystrophy: initial experience. Radiology. 2002; 225(1):245-252.
PMID: 12355012
24. Giardiello FM, Hylind LM, Yang VW, Krush AJ, Petersen GM, Brensinger JD, Piantadosi S, Garrett ES, Offerhaus GJA,
and Hamilton SR. Primary Chemoprevention in Familial Adenomatous Polyposis. N Engl J Med. 2002; 346:1054-9.
PMCID: PMC2225537; PMID: 11932472
25. Garrett ES, Eaton WW, Zeger SL. Methods for evaluating the performance of diagnostic tests in the absence of a gold
standard: a latent class model approach. Stat Med. 2002; 21(9) 1289-1307. PMID: 12111879
26. Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Elza-Brown K, Garrett ES, Armstrong DA. A phase I toxicity and
feasibility trial of sequential dose dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed
by high dose consolidation for high risk primary breast cancer. Breast Cancer Research and Treatment. 2002; 76(2): 145-
156. PMID: 12452452
27. Parmigiani G, Garrett E, Anbazhagan R, Gabrielson E. A Statistical framework for expression-based molecular
classification in cancer. Journal of the Royal Statistical Society, Series B, with discussion. 2002; 64:717-736.
28. Nilsson KR, Berenholtz SM, Dorman T, Garrett E, Kaufman HS, Pronovost PJ. Preoperative predictors of blood
transfusion in colorectal cancer surgery. Journal of Gastrointestinal Surgery. 2002; 6(5): 753-762. PMID: 12399066
29. Tanavde VM, Malehorn MT, Lumkul R, Gao Z,Wingard J, Garrett ES, Civin CI. Human stem-progenitor cells from
neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. Experimental
Hematology. 2002; 7(2):816-823. PMID: 12135681
ELIZABETH GARRETT-MAYER PAGE 17 OF 31 MAY 16
30. Yoon DS,Wersto RP, ZhouW, Chrest FJ, Garrett ES, Kwon TK, Gabrielson ES. Variable levels of chromosomal
instability and mitotic spindle checkpoint defects in breast cancer. American Journal of Pathology. 2002; 161: 391-397.
PMCID: PMC1850727; PMID: 12163363
31. Fujii H, Anbazhagen R, Bornman DM, Garrett ES, Perlman E, Gabrielson E. Mucinous cancers have fewer genomic
alterations than more common classes of breast cancer. Breast Cancer Research and Treatment. 2002; 76(3): 255-260.
PMID: 12462386
32. Nallamshetty L, Ahn NU, Ahn UM, Buchowski JM, An HS, Rose PS, Garrett ES, Erkula G, Kebaish KM, Sponseller PD.
Plain radiography of the lumbosacral spine in Marfan syndrome. Spine Journal. 2002; 2(5):327-33. PMID: 14589463
33. Ling, S.M., Fried, L.P, Garrett, E.S., Fan, M.Y., Rantanen, T., Bathon, J.M. Knee osteoarthritis compromises early
mobility function: the women's health and aging study II. The Journal of Rheumatology. 2003; 30(1): 114-120. PMID:
12508399
34. Morrison W, Haas E, Shaffner D, Garrett E, Fackler J. Noise, stress and annoyance in a pediatric intensive care unit.
Critical Care Medicine, 2003; 31(1): 113-199. PMID: 12545003
35. Scharpf R, Garrett ES, Hu J, Parmigiani G. Statistical Modeling and Visualization of Molecular Profiles in Cancer.
Biotechniques. 2003; 34: S22-S29. PMID: 12664681
36. Kominsky S, Argani P, Evron E, Korz D, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi O, Sukumar S. Loss of
tight junction protein claudin-7 correlates with histologicl grade in both ductal carcinoma in situ and invasive ductal
carcinoma of the breast. Oncogene. 2003; 22(13): 2021-2033. PMID: 12673207
37. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H., Christensen SB, Isaacs J. Prostate-specfic
antigen (psa) activated thapsigargin in prodrug as targeted therapy for prostate cancer. Journal of the National Cancer
Institute. 2003; 95(13): 990-1000. PMID: 12837835
38. Kozlow J, Berenholtz S, Garrett E, Dorman T, Pronovost P. Epidemiology and impact of aspiration preumonia in patients
undergoing surgery in maryland 1999 - 2000. Critical Care Medicine. 2003;31(7): 1930-1937. PMID: 12847385
39. Derr R, Garrett ES, Stacey GA, Saudek CD. Is hemoglobin a1c affected by glycemic instability? Diabetes Care. 2003;
26(10): 2728-2733. PMID: 14514571
40. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT. HER-2/neu-
specific monoclonal antibodies collaborate with HER-2/neu-targeted granucolyte macrophage colony-stimulating factor
secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in HER- 2/neu-
transgenic mice. The Journal of Immunology. 2003; 171: 2161-2169. PMID: 12902523
41. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrota J, Polyak C, Sukumar S, Argani P. DNA methylation of Rassf1a,
Hin-1, Rar-, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. International Journal of Cancer. 2003;
107: 970-975. PMID: 14601057
42. Handa VL, Garrett ES, Hendrix S, Yasmeen S, Gold E, Robbins J. Progression and remission of pelvic organ prolapse: a
longitudinal study of menopausalwomen. American Journal of Obstetrics and Gynecology. 2004; 190: 27-32, 2004.
PMID: 14749630
43. Parmigiani G, Garrett ES, Anbazhagan R, Gabrielson E. The molecular classification of lung cancer: a cross-study
comparison of gene expression data sets. Chest. 2004 May; 125(5 Suppl):103S. PMID: 15131026
44. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett
ES, Parmigiani G, Broome C, Sukumar S. ER/PR-negative breast cancers of young african american women have a higher
frequency of methylation of multiple genes than those of caucasian women. Clinical Cancer Research. 2004; 10(6): 2052-
2057. PMID: 15041725
45. Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler, MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E,
Argani P, Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and
lung. Clinical Cancer Research. 2004; 10(9): 3104-3109. PMID: 15131050
ELIZABETH GARRETT-MAYER PAGE 18 OF 31 MAY 16
46. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML. Oral human papillomavirus
infection in adults is associated with sexual behavior and HIV serostatus. Journal of Infectious Disease. 2004; 189(4):
686-698. PMID: 14767823
47. Rudek MA, Sparreboom A, Garrett ES, Gianni L, Vigano L, Armstrong DK,Wolff AC, Verweij J, Baker SD. Factors
affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. European Journal of Cancer.
2004; 40: 1170-1178. PMID: 15110880
48. Masayesva B, Ha P, Garrett-Mayer E, Pilkington T, Mao R, Pevsner J, Speed T, Benoit N, Moon CS, Sidransky D,
Westra W, Califano J. Gene expression alterations over large chromosomal regions in cancers includes multiple genes
unrelated to malignant progression. Proceedings of the National Academy of Sciences. 2004; 101(23): 8715-8720.
PMCID: PMC423261; PMID: 15155901
49. Cope L, Zhong X, Garrett E, Parmigiani G. MergeMaid: R Tools for Merging and Cross-Study Validation of Gene
Expression Data. Statistical Applications in Genetics and Biology. 2004; 3(1): Article 29. PMID: 16646808
50. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural History of Paroxysmal Nocturnal Haemoglobinuria using
modern diagnostic assays. British Journal of Haematology. 2004; 26(1): 133-138. PMID: 15198744
51. Kwiterovich PO, Virgil DG, Garrett ES, Otvos J, Driggers R, Blakemore K, Cockrill S, Macfarlane RD. Lipoprotein
heterogeneity at birth: influence of gestational age and race on lipoprotein subclasses and lp(a) lipoprotein. Ethnicity and
Disease. 2004; 14(3): 351-359. PMID: 15328936
52. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Garrett-Mayer E, Argani P, Sukumar S. Quantitative multiplex
methylation-specific PCR assay for the detection of promoter methylation in multiple genes in breast cancer. Cancer
Research. 2004; 64(13):4442-4452. PMID: 15231653
53. Kasamon YL, Jones RJ, Diehl LF, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RF, Zhang Z, Flinn IW.
Outcomes of Autologous and Allogeneic Blood or Marrow Transplantation for Mantle Cell Lymphoma. Biology of Blood
and MarrowTransplantation. 2004; 11: 39-46. PMID: 15625543
54. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E. Hypermethylation in
histologically distinct classes of breast cancer. Clinical Cancer Research. 2004; 10: 5998-6005. PMID: 15447983
55. Gitlin J, Cook LL, Linton OW, Garrett-Mayer E. Comparison of ‘ ‘B” Readers’ Interpretations of Chest Radiographs for
Asbestos Related Changes. Academic Radiology. 2004; 11: 843-856. PMID: 15354304
56. Hurst SA, Teagarden JR, Garrett E, Emanuel EJ. Conserving Scarce Resources: Willingness of Health Insurance
Enrollees to Choose Cheaper Options. Journal of Law, Medicine, and Ethics. 2004; 32: 496-499. PMID: 15490596
57. Berenholtz SM, Pronovost PJ, Lipsett PA, Hobson D, Earsing K, Farley JE, Milanovich S, Garrett-Mayer E, Winters BD,
Rubin HR, Dorman T, Perl TM. Eliminating Catheter-Related Bloodstream Infections in the Intensive Care Unit. Critical
Care Medicine. 2004; 32(10): 2014-2020. PMID: 15483409
58. Garrett ES, Parmigiani G. A nested unsupervised approach to identifying novel molecular subtypes. Bernoulli. 2004;
10(6): 951-956.
59. Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Hermann JG, Davidson NE. Epigenetic regulation of protein phosphatase
2A (PP2A), lymphoactin (XCL1), and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer
Biology and Therapy. 2004; 3(12): 304-12. PMID: 15662126
60. Ulrich CM, Danis M, Koziol D, Garrett-Mayer E, Hubbard R, Grady C. Does it pay to pay? A randomized trial of
financial incentives in survey research. Nursing Research. 2005; 54(3):178-183. PMID: 15897793
61. Ravi R, Jain AJ, Schulick RD, Pham, Prouser TS, Allen H, Garrett-Mayer E, Yu H, Pardoll D, Ashkenazi A, Bedi A.
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2
Ligand/TRAIL. Cancer Research. 2004; 64: 9105-9114. PMID: 16452233
ELIZABETH GARRETT-MAYER PAGE 19 OF 31 MAY 16
62. Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw AP, Civelek AC, Zeiger MA. Effect of
calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004;
136: 1199-1204.U PMID: 15657576
63. Chen H, Rubin E, Zhang H, Chung S, Jie CC, Garrett E, Biswal S, Sukumar S. Identification of transcriptional targets of
HOXA5. Journal of Biochemistry and Molecular Biology. 2005; 280(19):1973-1980. PMID: 15757903
64. Kwiterovich PO, Cockrill SL, Virgil DG, Garrett ES, Otvos J, Knight-Gibson C. An elevated large high-density
lipoprotein enriched in apolipoprotein C-I: A novel biochemical marker in infants of lower birth weight and younger
gestational age. Journal of the American Medical Association. 2005; 293(15): 1891-1899. PMID: 15840864
65. Pace C, Talisuna A, Wendler D, Maiso F, Wabwire-Mangen F, Bakyaita N, Okiria E, Garrett-Mayer ES, Emanuel E,
Grady C. Quality of parental consent in a Ugandan malaria study. American Journal of Public Health. 2005; 95(7):1184-
1189. PMCID: PMC1449338; PMID: 15933235
66. Kasamon YL, Byrd JC, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Flinn IW. Phase I study of
interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic
leukemia. Clinical Cancer Research. 2005;11(23):8413-8417.U PMID: 16322303
67. Diaz LA Jr, Cheong I, Foss CA, Zhang X, Peters BA, Agrawal N, Bettegowda C, Karim B, Liu G, Khan K, Huang X,
Kohli M, Dang LH, Hwang P, Vogelstein A, Garrett-Mayer E, Kobrin B, Pomper M, Zhou S, Kinzler KW, Vogelstein B,
Huso DL. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicological Sciences. 2005; 88(2): 562-
575. PMID: 16162850
68. Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP, Zeiger MA. 25-hydroxyvitamin D
deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally
invasive parathyroidectomy. Surgery. 2005;138(6): 1018-1025; discussion 1025-1026. PMID: 16360386
69. Allen E, Piontek KB, Garrett-Mayer E, Garcia-Gonzalez M, Gorelick KL, Germino GG. Loss of polycystin-1 or
polycystin–2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone
receptors. Human Molecular Genetics. 2006; 15(1):11-21.
70. Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, Prouse T, Jalla S, Zhou XZ, Garrett-Mayer E, Kaufmann SH, Schulick
RD, Pardoll DM, Bedi A. Resistance of Cancers to Immunologic Cytotoxicity and Adoptive Immunotherapy via XIAP
expression and co-existing defects in Mitochondrial Death Signaling. Cancer Research. 2006; 66(3): 1730-1739. PMID:
16452233
71. Garrett-Mayer, E. The Continual Reassessment Method for Dose-Finding: A Tutorial. Clinical Trials. 2006; 3(1): 57-
71. PMID: 16539090
72. Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar
S. Ductal access for prevention and therapy of mammary tumors. Cancer Research. 2006; 66(2):638-645. PMID:
16423990
73. Lo PK, Mehrotra J, D’Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic Suppression of Secreted
Frizzled Related Protein 1 (SFRP1) Expression in Human Breast Cancer. Cancer Biology and Therapy. 2006 Mar 6; 5(3)
281-286.U PMID: 16410723
74. Landa R, Garrett-Mayer E. Development in Infants with Autism Spectrum Disorders: A Prospective Study. Journal of
Child Psychology and Psychiatry. 2006; 47(6):629-638. PMID: 16712640
75. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM,
Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus Host Reactions and the Effectiveness of Donor
Lymphocyte Infusions. Biological Blood Marrow Transplantation. 2006; 12(4):414-421. PMID: 16545725
76. Shalowitz DI, Garrett-Mayer E, Wendler D. The Accuracy of Surrogate Decision-Makers: A Systematic Review.
Archives of Internal Medicine (Review). 2006; 166(5):493-497. PMID: 16534034
77. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan
ELIZABETH GARRETT-MAYER PAGE 20 OF 31 MAY 16
SA, Sukumar S. Quantitative Multiplex-Methylation Specific PCR Analysis Doubles Detection of Tumor Cells in Breast
Ductal Fluid. Clinical Cancer Research. 2006 Jun 1; 12(11 Pt 1): 3306-3310. PMID: 16740751
78. Shankar S, Klassen AC, Garrett-Mayer E, Houts PS, Wang T, McCarthy M, Cain R, Zhang L. Evaluation of a nutrition
education intervention for women residents of Washington, DC, public housing communities. Health Educ Res. 2007
Jun;22(3):425-37. PMID: 16982649
79. Hurst SA, Slowther AM, Forde R, Pegoraro R, Reiter-Theil S, Perrier A, Garrett-Mayer E, Danis M. Prevalence and
determinants of physician bedside rationing: data from Europe. Journal of General Archives of Internal Medicine. 2006
Nov: 21 (11): 1138-1143. PMCID: PMC1831659; PMID: 16836629
80. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and
allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow
Transplant. 2006 Sep; 12(9): 965-972. PMID: 16920563
81. Hurst S., Perrier A., Pegoraro R., Reiter-Theil S., Forde R., Slowther A., Garrett-Mayer E., Danis M.: European
Physicians' Experience with Ethical Difficulties in Clinical Practice. Journal of Medical Ethics. 2007 Jan; 33(1): 51-57.
PMID: 17209113
82. Lancet, JE, Gojo I, Gotlibn J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH,
Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in
poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4): 1387-
1394. PMCID: PMC1794070 PMID: 17082323
83. Ulrich CM, Danis M, Ratcliffe SJ, Garrett-Mayer E, Koziol D, Soeken KL, Grady C. Ethical conflict in nurse
practitioners and physician assistants in managed care. Nursing Research. 2006 Nov-Dec; 55(6):391-401. PMID:
17133146
84. Sullivan M, Finelli J, Marvin A, Garrett-Mayer E, Bauman M, Landa R. Response to joint attention in toddlers at risk for
austism spectrum disorder: a prospective study. J Autism Dev Disord. 2007 Jan; 37(1):37-48. PMID: 17216332
85. Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous
thromboembolism and perioperative allogeneic transfusion. Archives of Surgery. 2007 Feb; 142(2): 126-132. PMID:
17309963
86. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA,
Deweese TL. Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse
After Definitive Radical Retropubic Prostatectomy or Radiotherapy. Urology. 2007 Mar;69(3):526-31. PMID: 17382158
87. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR.
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar
7;99(5):376-85. PMID: 17341729
88. Shalowitz DI, Garrett-Mayer E, Wendler D. How Should Treatment Decisions Be Made for Incapacitated Patients, and
Why? PLoS Med. 2007 Mar 13;4(3):e35. PMCID: PMC1820603; PMID: 17388655
89. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo
M. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein
tau is predictive of their activity in pancreatic cancer. Molecular Cancer Therapeutics. 2007 May;6(5):1509-16 PMID:
17483439
90. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, Dipaola RS, Roth BJ, Cookson
MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger
MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional
pilot study. Journal of Urology. 2007 May;177(5):1777-81. PMID: 17437819
91. Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent
uterine leiomyosarcoma. Gynecol Oncol. 2007 Jul;106(1):82-8. PMID: 17434579
ELIZABETH GARRETT-MAYER PAGE 21 OF 31 MAY 16
92. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani
P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and Clinical Evaluation of Sulforaphane for
Chemoprevention in the Breast. Carcinogenesis. 2007 Jul;28(7):1485-90. PMID: 17347138
93. Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, Garrett-Meyer E [sic], Sukumar S.A Comparative Study of Korean with
Caucasian Breast Cancer Reveals Frequency of Methylation in Multiple Genes Correlates with Breast Cancer in Young,
ER,PR-negative Breast Cancer in Korean Women. Cancer Biology Therapy 2007 Apr 23;6(7). PMID: 17611401
94. Landa RJ, Holman KC, Garrett-Mayer E. Social and communication development in toddlers with early and later
diagnosis of autism spectrum disorders. Archives of General Psychiatry. 2007 Jul;64(7):853-64. PMID: 17606819
95. Koyfman SA, Agrawal M, Garrett-Mayer E, Krohmal B, Wolf E, Emanuel EJ, Gross CP. Risks and benefits associated
with novel phase 1 oncology trial designs. Cancer. 2007 Sep 1;110(5):1115-24. PMID: 17628485
96. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E [sic], Dackiw AP, Tufano RP, Zeiger MA,
Ziessman HA. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi
parathyroid scintigraphy. Journal of Nuclear Medicine. 2007 Jul: 48(7): 1084-1089. PMID: 17574983
97. Armstrong AJ, Garrett-Mayer E, Ou Yang Y-C, Carducci MA, Tannock I, de Wit R, Eisenberger MA. Prostate-specific
antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 2007
Sep; 25(25): 3965-3970. PMID: 17761981
98. Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky
R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of Autologous
Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma.
Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191. PMCID: PMC2271148; PMID: 17889355
99. Garrett-Mayer E, Parmigiani G, Zhong X, Cope L, Gabrielson E. Cross-study validation and combined analysis of gene
expression microarray data. Biostatistics,2008 Apr;9(2):333-54. PMID: 17873151
100. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in Men with Non-Metastatic Prostate
Cancer Treated with Hormone Therapy: A Quantitative Systematic Review. Journal of Clinical Oncology, 2007 Nov 1;
25(31): 4998-5008. PMID: 17971600
101. Armstrong AJ, Garrett-Mayer ES, Ou Yang YC, de Wit R, Tannock IF, Eisenberger MA. Contemporary Prognostic
Nomogram for Men With Hormone-Refractory Metastatic Prostate Cancer (HRPC): A TAX327 Study Analysis. Clinical
Cancer Research, 2007 Nov 1; 13(21): 6396-6403. PMID: 17975152
102. Klassen AC, Garrett-Mayer E, Houts PS, Shankar S, Torio CM. The relationship of body size to participation and
success in a fruits and vegetables intervention among low-income women. Journal of Community Health, 2008
Apr;33(2):78-89. PMID: 18074208
103. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose
escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC
Cancer, 2007 Dec 20; 7:231. PMCID: PMC2241632 PMID: 18096059
104. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW,
Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH,
Sidransky D, Califano JA. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis
Tool for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Reseach 2008 14: 97-107. PMID: 18172258
105. Hooker A, Ten Tije A, Carducci M, Weber J, Garrett-Mayer E, Gelderblom H, McGuire W, Verweij J, Karlsson M,
Baker S. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function:
Incorporating Cytochrome P450 3A Activity Measurements. Molecular Therapeutics 2008 Jan 9. PMID: 18183036
106. Choti MA, Kaloma F, de Oliviera ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM Patient variability in
intraoperative ultrasonographic characteristics of colorectal liver metastases. Archives of Surgery 2008 Jan; 143(1): 29-34.
PMID: 18209150
ELIZABETH GARRETT-MAYER PAGE 22 OF 31 MAY 16
107. Warlick ED, O’Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky RA, Fuchs EJ, Huff
CA, Luznik L, Matsui WH, Ambinder R, Jones RJ, Smith BD. Myeloablative allogeneic bone marrow transplant using T-
cell depleted allografts followed by post-transplant GM-CSF in high risk myelodysplastic syndromes. Leukemia Research,
2008 Sep;32(9):1439-47. PMID: 18261793
108. Abukhdeir AM, Vitolo MI, Argani P, DeMarzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C,
Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth
of breast cancer due to p21 loss. Proceedings of the National Academy of Sciences, USA. 2008 Jan 8;105(1):288-93. PMCID: PMC2224203; PMID: 18162533
109. Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M. A simple two-gene prognostic model
for adenocarcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery. March 2008; 135(3): 627-634. PMID:
18329483
110. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo
AM, Herman JG. Impact of DNA Methylation on the identification of aggressive prostate cancer. Urology, 2008 Apr 1.
PMID: 18387661
111. Diaz-Montero CM, Salem M, Garrett-Mayer E, Cole DJ, Montero AJ. Increased Levels of Circulating Myeloid-Derived
Suppressor Cells in Solid Tumor Patients Correlate With Advanced Clinical Cancer Stage, Increased Tumor Burden, and
Cyclophosphamide Containing Chemotherapy. Cancer Immunology, Immunotherapy, 30 April 2008. PMID: 18446337
112. McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer E, Sharma AK, Day TA, Gillespie MB. Effect of Body Mass
Index on Chemoradiation Outcomes in Head and Neck Cancer. Laryngoscope, 2008 Jul;118(7):1180-5. PMID: 18475213
113. Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E.
Phase II trial of the oral farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) as maintenance therapy in first
complete remission in adults with acute myelogenous leukemia and poor risk features. Clinical Cancer Research, 2008
May 15;14(10):3077-82. PMID: 18483374
114. Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Symptoms,
Supportive Care Needs, and Function in Cancer Patients: How Are They Related? Quality of Life Research, May 21,
2008. PMID: 18493865
115. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, Benjamin K, Hoda R, Krishna M, Romano M, Wallace
M, Garrett-Mayer E, Mitas M. beta(2)microglobulin mRNA expression ratios are prognostic for lymph node metastasis
in colorectal cancer patients. British Journal of Cancer, 2008 Jun 17;98(12):1999-2005. PMID: 18506145
116. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel Role of
Thromboxane Receptors {beta} Isoform in Bladder Cancer Pathogenesis. Cancer Res. 2008 Jun 1;68(11):4097-4104.
PMID: 18519668
117. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA,
Laheru D, Donnehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous
reassessment method (mCRM) –based, dose finding study of rapamycin (sirolimus) in adult patients with solid tumors.
Journal of Clinical Oncology 2008 Sep 1;26(25):4172-9. PMID: 18757332
118. Su S-C, Caffo B, Garrett-Mayer E, Bassett SS. Modified test statistics by inter-voxel variance shrinkage with an
application to fMRI. Biostatistics 2009 Apr;10(2):219-27. PMID: 18723853
119. Blum C, Graham A, Yousefzadeh M, Shrout J, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace
M, Mitas M. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.
International Journal of Oncology 2008 Sep;33(3):579-84. PMID: 18695889
120. Hall PD, Beagle KL, Garrett-Mayer E, Frankel AE. Reducing Anti-DT IgG Concentrations to Improve the efficacy of a
Diphtheria Fusion Protein. Anti-Cancer Drugs. 2008 Nov;19(10):1007-1011. PMID: 18827566
121. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, Ironside V,
Talbot T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MK, Wright JJ, Garrett-Mayer
ELIZABETH GARRETT-MAYER PAGE 23 OF 31 MAY 16
E*, Kaufmann SH*. Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia: A
Preclinical and Phase I Trial of the Farnesyltransferase Inhibitor Tipifarnib (R115777, Zarnestra) Combined with
Etoposide. Blood, 2009 May 14;113(20):4841-52. (* denotes equal contribution of last two senior authors). PMID:
19109557
122. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors
associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-
stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2009;74:1108-1113. PMID: 19084345
123. Watkins JM, Marshall DT, Patel S, Giglio P, Herrin AE, Garrett-Mayer E, Jenrette JM. High-Dose Radiotherapy to 78
Gy With or Without Temozolomide for High Grade Gliomas. Journal of Neuro-Oncology. 2009 Jul;93(3):343-8. PMID:
19142584
124. Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma
AK. Toxicity and survival outcomes of hyperfractionated re-irradiation split-course radiotherapy and concurrent
chemotherapy in loco-regionally recurrent, previously irradiated head and neck cancers. Head & Neck, 2009;31:493-502.
PMID: 19156831
125. Nietert PJ, Ravenel JG, Leue WM, Miller JV, Taylor KK, Garrett-Mayer E, Silvestri GA. Imprecision in automated
volume measurements of pulmonary nodules and its effect on the level of uncertainty in volume doubling time estimation.
Chest. 2009 June; 135(6): 1580-7. PMID: 19141526
126. Nonemaker JM, Garrett-Mayer E, Carpenter MJ, Ford MW, Silvestri G, Lackland DT, Alberg AJ. The Risk of Dying
from Lung Cancer by Race: A Prospective Cohort Study in a Biracial Cohort in Charleston, South Carolina. Annals of
Epidemiology. 2009 May;19(5):304-10. PMID: 19269855
127. Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange J, Jacobs L, Emens L, Armstrong
D, Fetting J, Garrett-Mayer E, Davidson NE, Wolff AC. Partial Breast Irradiation and Concurrent dose-dense
Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 2009 Jun 10; 27(1):2816-22. PMID: 19332718
128. Loeb DM, Garrett-Mayer E, Hobbs R, Prideaux AR, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Dose-
Finding Study of 153Sm-EDTMP in Patients with Poor Prognosis Osteosarcoma. Cancer. 2009 Jun 1;115(11):2514-22]
PMID: 19338063
129. Carpenter MJ, Garrett-Mayer E, Vitoc C, Cartmell K, Biggers S, Alberg A. Adolescent Light and Intermittent Smokers:
Favorable Views of Tobacco Yet Receptive to Cessation. Nicotine and Tobacco Research. 2009 Apr;11(4):348-55.
PMID: 19366985
130. Yang C, Garrett-Mayer E, Schneider JS,Gollomp SM,Tilley BC. Repeatable Battery for Assessment of
Neuropsychological Status in Early Parkinson’s Disease. Movement Disorders, 2009 Jul 30; 24(10): 1453-60. PMID:
19452561.
131. Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW.
Concordance of cancer patients' function, symptoms, and supportive care needs. Quality of Life Research. 2009 Oct;
18(8):991-8. PMID: 19657724.
132. Berenholtz SM, Pham JC, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB, Nundy S, Dorman T, Ness PM, Klag
MJ, Pronovost PJ, Kebaish KM. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal
surgery. Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096-103. PMID: 19730217.
133. Harper JL, Watkins JM, Zauls AJ, Wahlquist AE, M.S, Garrett-Mayer E, Baker MK, Cole DJ, Dragun AE, Jenrette JM.
Six-year experience: long term disease control outcomes for partial breast irradiation using MammoSite balloon
brachytherapy. Am J Surg. 2010 Feb; 199(2): 204-9 PMID: 19837390.
134. Cunningham JC, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B. Racial differences in the incidence of breast cancer
subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes and Control 2010 Mar; 21(3):
399-409. PMID: 20024610
135. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of Survival following First-Line
ELIZABETH GARRETT-MAYER PAGE 24 OF 31 MAY 16
Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research, 2010 Jan 1; 16(1):
203-211.
136. Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E, Gillespie MB, Day TA, Sharma AK. Low-dose
weekly platinum-based chemoradiation for advanced head/neck cancer. Laryngoscope Feb 2010 120(2):236-42.
137. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C,
Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden
in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-
47. PMID: 20048335.
138. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk
febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb;19(2):231-7 PubMed PMID: 20069435.
139. Nalugoda F, Wagman J, Kiddugavu M, Kiwanuka N, Garrett E, Gray RH, Serwadda D, Wawer MJ, Emanuel EJ. Is there
coercion or undue inducement to participate in health research in developing countries? An example from Rakai, Uganda. J
Clin Ethics. 2009 Summer;20(2):141-9. PubMed PMID: 19554819.
140. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors
associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-
stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:1108-1113. PMID: 19084345
141. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to Phase 1 Clinical Trial Design Focused on Safety,
Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer
Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010 Mar 15; 16(6):1726-36. PMID: 20215542
142. El-Zawahry AM, Clarke HS, Eskridge MR, Rieter W, Onicescu G, Garrett-Mayer E, Gordon LL, Keane TE. Capromab
Pendetide Scanning Has a Potential Role in Optimizing Patient Selection for Salvage Cryosurgical Ablation of the Prostate.
Urology, 2010 Nov; 76(5): 1162-7.
143. Watkins JM, Fortney JA, Wahlquist AH, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK.
Once-daily radiotherapy to >59.4 Gy versus twice-daily radiotherapy to >45 Gy with concurrent chemotherapy for limited-
stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun;28(5):340-8.
PMID: 20585921
144. Ford ME, Wahlquist AE, Ridgeway C, Streets J, Mitchum KA, Harper RR Jr, Hamilton I, Etheredge JJ, Jefferson MS,
Varner H, Campbell K, Garrett-Mayer E. Evaluating an Intervention to Increase Cancer Knowledge in Racially Diverse
Communities in South Carolina. Patient Educ Couns. 2011 May; 83(2)” 256-60. PMID: 20674239
145. Ruppert BN, Watkins, JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK.
Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal
cancer. Am J Clin Oncol 2010;33:346-352.
146. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK.
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer (SCLC): disease
control, patterns of failure, and survival. J Med Imaging Radiat Oncol 2010;54:483-489.
147. Zauls AJ, Watkins JM, Wahlquist AE, Brackett NC, Aguero EG, Baker MK, Jenrette JM, Garrett-Mayer E, Harper JL.
Outcomes in Women Treated with MammoSite Brachytherapy or Whole Breast Irradiation Stratified by ASTRO
Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1): 21-9.
PMID: 20951508.
148. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin
HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011 Jan 1; 300(1): 66-78. PMID: 20980099.
149. Watkins JM, Wahlquist AE, Zauls AJ, Fields EC, Garrett-Mayer E, Aguero EG, Silvestri GA, Sharma AK. High-dose
fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small cell lung cancer. J Med Imaging Radiat
Oncol. 2010 Dec; 54(6): 554-61 PMID: 21199434.
ELIZABETH GARRETT-MAYER PAGE 25 OF 31 MAY 16
150. Fisher CS, Cole DJ, Mitas M, Garrett-Meyer E (sic), Metcalf JS, Gillanders WE, Mikhitarian K, Urist MM, Mann GB,
Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL,
Frykberg E, Yeh K, Bell RM, Baker MK. Molecular detection of micrometastatic breast cancer in histopathology-negative
axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort
study. Ann Surg Oncol. 2010 Oct;17 Suppl 3:312-20. PubMed PMID:20853052.
151. Scharpf R, Iacobuzio-Donahue CA, Cope L, Ruczinski I, Lakkar S, Garrett-Mayer E, Parmigiani G. Cross-platform
comparison of two pancreatic cancer phenotypes. Cancer Informatics. 2010 Nov 1; 9:257-264.
152. Leoutsakos JM, Bandeen-Roche K, Garrett-Mayer E, Zandi P. Incorporating Scientific Knowledge into Phenotype
Development: Penalized Latent Class Regression. Statistics in Medicine. 2011 Mar 30; 30(7): 784-98 PMID: 21394753.
153. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Feting JH, Emens LA,
Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel Metabolism is Not Altered by Imatinib: Findings from an Early
Phase Study in Metastatic Breast Cancer. Breast Cancer Research and Treatment 2011 May; 127(1): 153-62. PMID:
213508820.
154. Van Meter E, Garrett-Mayer E, Bandyopadhay D. Proportional odds model for dose finding clinical trial designs with
ordinal toxicity grading. Statistics in Medicine. 2011Jun 30; 30(17): 2070-80. PMID: 21344472; PMCID: PMC3117067.
155. Kearney PL, Watkins JL, Shirai K, Wahlquist AE, Fortney JA, Garrett-Mayer E, Gillespie MB, Sharma AK. Salvage
Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent
Chemoradiotherapy Case Series and Review of the Literature. McGill Journal of Medicine 2011 Jun; 13(2): 29.
156. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A Novel Extracellular Hsp90
Meditated Function for LRP1 Regulates EphA2 Dependent Gioblastoma Invasion. PLoS One. 2011 Mar 8; 6(3): e17649.
PMID: 21408136.
157. Ryan, K.K., Garrett-Mayer, E., Alberg, A.J., Cartmell, K.B., & Carpenter, M.J. Predictors of cessation pharmacotherapy
use among African American and non-Hispanic white smokers. Nicotine & Tobacco Research. 2011 Aug;13(8):646-52.
PMID: 21464200.
158. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination Therapy
of recurrent prostate cancer with proteasome inhibitor Bortezomib plus hormone blockade. Cancer Biol Ther, 2011 July
15; 12(2): 119-24. PMID: 21532336.
159. Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA. Utilizing endobronchial
ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology
Interv Pulmonol 2011 Oct; 18(4):317-21. PMIS 23208625
160. Wang Memoli, J, El-Bayoumi E, Pastis N, Tanner N, Gomez M, Huggins J, Onicescu G, Garrett-Mayer E, Armeson K,
Taylor K, Silvestri G. Using EBUS Features to Predict Lymph Node Metastasis in Patients with Lung Cancer. Chest, 2011
Dec; 140(6): 1550-6. PMID: 21636663; PMCID: PMC3231960.
161. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G,
Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the
immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011 Aug 25; 118(8): 2254-65. PMID:
21734236.
162. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS,
Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon G, Shirai K, Ogretmen B. Results of a Phase II Trial of
Gemcitabine plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-ceramide as a Novel
Biomarker for Monitoring Response. Clin Cancer Res. 2011 Sep 15; 17(18): 6097-105. PMID 21791630. PMCID:
PMC3176980.
163. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers P, Wright LA,
Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson
NE, Stearns V. Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant
Anastrozole. Cancer Prevention Research. 2011 Dec; 4(12): 1993-2001. PMID: 21885816.
ELIZABETH GARRETT-MAYER PAGE 26 OF 31 MAY 16
164. Karp JE, Vener TI, Raponi M, Greer J, Ritchie EK, Morris LE, Smith BD, Feldman EJ, Gore SD, Levis MJ, Galkin S,
Malek S, Gocke CD, Roboz GR, Carraway HE, McDevitt MA, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ,
Garrett-Mayer E. Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly
adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 5;119(1):55-63.
165. Curran JN, Garrett-Mayer E, Carpenter MJ, Ford ME, Silvestri GA, Lackland DT, Alberg AJ. Cigarette Smoking and the
Risk of Dying from Tobacco-related Malignancies by Race. Anticancer Research . 2011 Nov; 31(11):3891-5.
166. Logan S, Nicholas J, Carpenter L, King L, Garrett-Mayer E, Charles J. High Prescription Drug Utilization and
Associated Costs among Medicaid-eligible Children with Autism Spectrum Disorders Identified by a Population-based
Surveillance Network. Annals of Epidemiology.2012 Jan; 22(1): 1-8.
167. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL,
Abbruzzese JL, Thomas MB. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and
Predictors of Outcome: Final Results of a Phase II Trial. Oncology. 2012 Feb 7;82(2):67-74.
168. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E
(sic), Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. Phase 2 study of neoadjuvant
treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with
HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012 Feb;132(1):215-23. PMCID:
PMC3697917.
169. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S.
Vitamin D3 supplementation at 4,000 IU per day for one year results in a decrease of positive cores at repeat biopsy in
subjects with low-risk prostate cancer under active surveillance. The Journal of Clinical Endocrinology & Metabolism,
2012 Apr 16 [Epub ahead of print].
170. Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15 week CHOP Protocol for the Treatment of Canine
Multicentric Lymphoma. Veterinary and Comparative Oncology, 2012 May 2 [Epub ahead of print].
171. Van Meter E, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the
continual ratio model: an extension of the continual reassessment method. Clinical Trials. 2012 Apr 30 [Epub ahead of
print].
172. Hudspeth MP, Heath TS, Chiuzan C, Garrett-Mayer E, Nista E, Burton L, Ragucci D. Folinic acid administration after
methotrexate graft-versus-host disease prophylaxis in pediatric allogeneic stem cell transplantation. Bone Marrow
Transplantation. 21 May 2012 [Epub ahead of print].
173. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Gore SD, Greer JM, Drye DM, Mackey K, Dorcy KS,
Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM.
A randomized Phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside
and mitoxantrone (FLAM) for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012
June 24 [Epub ahead of print].
174. Taylor R, Opfermann K, Jones BD, Terwilliger LE, McDonald DG, Ashenafi MS, Garrett-Meyer E [sic], Marshall DT.
Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical
tomotherapy. J Med Imaging Radiat Oncol. 2012 Jun;56(3):332-7. Epub 2012 Apr 11. PubMed PMID: 22697333.
175. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell
H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI. A
Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. Journal of
Immunology. 2012 Jul 13 [Epub ahead of print].
176. Garrett-Mayer E, Wagner CL, Hollis BW, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation (4000 IU per day for
one year) eliminates differences in circulating 25(OH)D between African-American and Caucasian men. The American
Journal of Clinical Nutrition. 2012 Aug; 96(2): 332-6.
ELIZABETH GARRETT-MAYER PAGE 27 OF 31 MAY 16
177. Ford ME, Wahquist AH, Blake R, Green C, Streets J, Fuller E, Johnson E, Jefferson MS, Etheredge JW, Varner H,
Johnson S, Glover SH, Turner DP, Garrett-Mayer E. Assessing an intervention to improve clinical trial perceptions
among predominantly African American communities in South Carolina. Progress in Community Health Partnerships:
Research Education and Action, 2012 Fall; 6(3): 249-63.
178. Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn
RA, Hidalgo M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Neoplasia. 2012 Aug 14; 14(8):690—701.
179. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam
SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B.
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-
RIPK1-dependent necroptosis. EMBO Mol Med. 2012 Nov 25 [Epub ahead of print].
180. Opferman K., Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant Radiotherapy and Lymph
Node Status for Pancreatic Cancer: Results of a Study from the Surveillance, Epidemiology, and End Results (SEER)
Registry Data. American Journal of Clinical Oncology. 2012 Dec 1 [Epub ahead of print].
181. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-
risk prostate cancer, and health disparities. The Journal of Steroid Biochemistry and Molecular Biology. 2012 Dec 7.
[Epub ahead of print].
182. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman C, Lacek AT,
Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI,
Guevara-Patino JA, Le Poole IC. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Science Translational
Medicine 2013 Feb 27; 5(174).
183. Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA,
Zhao M, Watkins SP Jr, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a
pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013 May;139(1):135-
43. doi: 10.1007/s10549-013-2516-z. PMID: 23588952 NIHMS: 468395.
184. Nassarre P, Roche J, Potiron VN, Howe P, Orch C, Baron A, Garrett-Mayer E, Drabkin H. Neuropilin-2 is upregulated
in lung cancer cells during TGFβ1-induced epithelialmesenchymal transition. Cancer Res. 2013 Dec 1;73(23):7111-21.
185. Rossmann C, Garrett-Mayer E, Haemmerich D. Dynamics of tissue shrinkage during ablative temperature exposures.
Physiol. Meas. 35 (2014) 55-67.
186. Morales C, Rachidi S, Hong F, Sun S, Ouyang X, Wallace C, Zhang Y, Garret-Mayer E (sic), Wu J, Liu B, Li Z. Immune
chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Research, 2014 Jan
15; 74(2):446-59.
187. Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C. Polymer-Enhanced Adenoviral
Delivery Increases Gene Expression in an Orthotopic Model of Bladder Cancer. Journal of Controlled Release, 2013 Dec
24: 176C:35-43.
188. Zellars R, Bravo PE, Tryggestad E, Hopfer K, Myers L, Tahari A, Asrari F, Ziessman H, Garrett-Mayer E. SPECT analysis
of Cardiac Perfusion Changes After Whole Breast/Chest Wall (BCW) Radiation Therapy with or without Active Breathing
Coordinator (ABC): Results of a Randomized Phase III Trial. International Journal of Radiation Oncology Biology and
Physics, 2014 Mar 15;88(4):778-85.
189. Esnaola N, Chaudhary U, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ,
Romagnuolo J, Orwat K, Marshall D. Phase II Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by
Selective Capecitabine-Based Chemoradiation in Patients with Nonmetastatic, Locally Advanced Pancreatic
Cancer. International Journal of Radiation Oncology, Biology and Physics. Int J Radiat Oncol Biol Phys. 2014
Mar 15;88(4):837-44.
ELIZABETH GARRETT-MAYER PAGE 28 OF 31 MAY 16
190. Lee M Ellis, David S Bernstein, Emile E Voest, Jordan D Berlin, Daniel J Sargent, Patricia Cortazar, Elizabeth Garrett-
Mayer, Roy S Herbst, Rogerio C Lilenbaum, Camelia Sima, Alan P Venook, Mithat Gönen, Richard L Schilsky, Neal J
Meropol, and Lowell E Schnipper. ASCO Perspective: Raising the Bar for Clinical Trials by Defining Clinically
Meaningful Outcomes. Journal of Clinical Oncology, 2014 Apr 20; 32(12): 1277-80.
191. Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical Esophageal Cancer: A Population Based
Study. Head and Neck, 2014 Mar 11. [Epub ahead of print].
192. Mathew AR, Wahlquist AE, Garrett-Mayer E, Gray KM, Saladin ME, Carpenter MJ. Affective Motives for Smoking
Among Early Stage Smokers. Nicotine Tob Res. 2014 Jun 12. pii: ntu093. [Epub ahead of print] PubMed PMID:
24924155.
193. Logan SL, Carpenter L, Leslie RS, Hunt KS, Garrett-Mayer E, Charles J, Nicholas JS. Rates and Predictors of Adherence
to Psychotropic Medications in Children with Autism Spectrum Disorders. J Autism Dev Disord. 2014 Jun 15. [Epub
ahead of print] PubMed PMID: 24929833.
194. Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Jack Longley B, Engelhard
VH, Mehrotra S, Le Poole IC. Immune Responses In A Mouse Model Of Vitiligo With Spontaneous Epidermal De- And
Repigmentation. Pigment Cell Melanoma Res. 2014 Jun 17. doi: 10.1111/pcmr.12284. [Epub ahead of print] PubMed PMID:
24935676.
195. Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt
K, Berg M, Uram J, Dauses T, Fetting JH, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for
HER-2+ Metastatic Breast Cancer. Cancer Immunology Research. 2014 Aug 12. Epub ahead of print.
196. Kummetha Venketa JK, An N, Stuart R, Costa L, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan
Z, Ogretmen B, Smith C, Kang Y. 1Inhibition of Sphingosine Kinase 2 Down-regulates the Expression of c-Myc and Mcl-1
and Induces Apoptosis in Multiple Myeloma. Blood. 2914 Aug 13. Epub ahead of print.
197. Sobelesky PM, Halushka P, Garrett-Mayer E, Smith MT, Moussa O. Regulation of the Tumor Suppressor FOXO3 by the
Thromboxane-A2 Receptors in Urothelial Cancer. 2014 Sep 9;9(9):e107530 PMCID: PMC4159332.
198. Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga O, Simms P, Beeson G, Voelkel-
Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S. Promoting Thiol Expression Increases The Durability
of Antitumor T cell Functions. Cancer Research, 2014 Aug 2 [Epub ahead of print].
199. Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP. KAT6A, a Chromatin Modifier
from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. Neoplasia. 2014 Aug; 16(8): 644-655.
PMCID in progress.
200. Chiuzan C, Garrett-Mayer E, Yeatts S. A likelihood-based approach for computing the operating characteristics of the 3+3
phase I clinical trial design with extensions to other A+B designs. Clinical Trials. 2014 Oct 27 [Epub ahead of print]. PMCID
in progress.
201. Somaiah N, Fidler M, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon G. Epidermal
growth factor receptor (EGFR) mutations are exceptionally rare in Thyroid transcription factor (TTF-1) negative
adenocarcinomas of the lung. Oncoscience. 2014 Aug 7;1(8):522-8. eCollection 2014. PMCID: PMC4278331
202. Kappler CS, Guest ST, Irish JC, Garrett-Mayer E, Kratche Z, Wilson RC, Ethier SP. Oncogenic signaling in amphiregulin
and RGFR-expression PTEN-null human breast cancer. Mol Onc 2014 Oct 23. [Epub ahead of print].
203. Smolka A, Halushka P, Garrett-Mayer E. The Faculty Costs to Educate a Biomedical Sciences Graduate Student. Life
Sciences Education. 2015 Mar 2.
204. Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams K, Johnson CB, Li
M, Scurti GM, Salem ML, Paulos CM, Garrett-Mayer E, Mehrotra S, Cole DJ. IL-12 enhances the function and anti-
tumor activity in murine and human CD8+ T cells. Cancer Immunology & Immunotherapy. 2015 Feb 13.
ELIZABETH GARRETT-MAYER PAGE 29 OF 31 MAY 16
205. Harper JL, DeCosta AM, Garrett-Mayer E, Sterba KR. Incorporating Patient Satisfaction Metrics In Assessing
Multidisciplinary Breast Cancer Care Quality. Southern Medical Journal 2015 Jun; 108(6):372-6 PMCID: PMC4470304
(available 2016-06-01.
206. Tirodkar TS, Lu P, Bai A, Scheffel MA, Gencer S, Garrett-Mayer E, Bielawska A, Ogretmen B, Voelkel-Johnson C.
Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-Terminal Kinase (JNK)-
Dependent Manner. The Journal of Biological Chemistry, Apr 3, 2015 (Epub).
207. Logan SL, Carpenter L, Leslie RS, Garrett-Mayer E, Hunt KJ, Charles J, Nicholas JS. Aberrant behaviors and co-occurring
conditions as predictors of psychotropic polypharmacy among children with autism spectrum disorders. J Child Adolesc
Psychopharmacol 2015 Apr 28 [Epub ahead of print].
208. Rhome RM, Wahlquist AE, Cooper, SL, Hill E, Garrett-Mayer E, Harper JL. Investigation of Epidemiological Factors as
Barriers to Indicated Radiation Therapy in Post−mastectomy Breast Cancer Patients in South Carolina. Journal of the South
Carolina Medical Association. 2015 March/April; 111(1):14-18.
209. Panneer Selvam S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, Skordalakes E, Ponnusamy S, Garrett-
Mayer E, Smith CD, Ogretmen B. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery
by allosterically mimicking protein phosphorylation. Sci Signal. 2015 Jun 16;8(381).
210. Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical esophageal cancer: A population-based
study. Head Neck. 2015 Jun;37(6):808-14. doi: 10.1002/hed.23678. Epub 2014 Jun 19. PubMed PMID: 24616217.
211. Marvella E Ford, Ph.D.; Wei Wei; Leslie A Moore; Dana R Burshell; Kimberly Cannady, Ph.D.; Franshawn Mack; Nnadozie
Ezerioha; Kelley Ercole; Elizabeth Garrett-Mayer, Ph.D. Evaluating the Reliability of the Attitudes To Randomized Trial
Questionnaire (ARTQ) in a Predominantly African American Sample. SpringerPlus, 2015 Aug 12; 4:411.
212. Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos
CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP. IL-12 conditioning improves retrovirally mediated transduction
efficiency of CD8(+) T cells. Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17. PubMed
PMID: 26182912.
213. Johnson CB, Riesenberg BP, May BR, Gilreath SC, Li G, Staveley-O'Carroll KF, Garrett-Mayer E, Mehrotra S, Cole DJ,
Rubinstein MP. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα
Dependent.Cancer Immunol Res. 2015 Aug 21. [Epub ahead of print] PubMed PMID: 26297711.
214. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR,Kraveka JM, Smith CD, Voelkel-
Johnson C. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in
accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther. 2015 Oct 22. pii: molcanther.0279.2015. [Epub
ahead of print] PubMed PMID: 26494858.
215. Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E,
Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP. IL-2Rα mediates temporal regulation
of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28;7(311):311ra170. doi:
10.1126/scitranslmed.aac8155. PubMed PMID: 26511507.
216. Timothy T. Spear, Glenda G. Callender, Jeffrey J. Roszkowski, Kelly M. Moxley, Kendra C. Foley, David C. Murray,
Gina M. Scurti, Patricia Simms, Mingli Li, Justin Thomas, Alexander Langerman, Elizabeth Garrett-Mayer, Yi. Zhang,
and Michael I. Nishimura, TCR gene-modified T cells can efficiently treat established hepatitis C associated hepatocellular
carcinoma tumors. Cancer Immunology, Immunotherapy. 2016 March; 65(3): 293-304.
217. Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC,
Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-
cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc
Biol. 2016 Feb 26.
218. Guest S, Krachte Z, Irish, J, Wilson R, Haddad R, Gray J, Garrett-Mayer E, Ethier S. Functional Oncogene Signatures
Guide Rationally Designed Combination Therapies to Synergistically Induce Breast Cancer Cell Death. Accepted,
ELIZABETH GARRETT-MAYER PAGE 30 OF 31 MAY 16
Oncotarget.
219. Carpenter MJ, Wahlquist AE, Burris JL, Gray KM, Garrett-Mayer E, Cumming KM, Alberg AJ. Snus undermines quit
attempts but not abstinence: a randomized clinical trial among US smokers. Tobacco Control. 2016 Apr 12.
UNON- PEER REVIEWED:U
1. HUZeger SL, Garrett ES. Rejoinder to latent class model diagnosis from a frequentist point of view. Biometrics. 2003; 59(1):
197-198UH.
2. HUBaker S, Garrett E, Giles F. Troxcitabine in patients with refractory leukemia -in reply. Journal of Clinical Oncology.
2002; 20(15): 3356-3361.U
3. HUGitlin JN, Cook LL, Linton OW, Garrett-Mayer E. Response to letters on B-readers study. Academic Radiology. 2004;
11(12):1402-1404.U
USCHOLARLY BOOKS AND MONOGRAPHS:
1. Parmigiani G, Garrett ES, Irizarry RA, Zeger SL. The Analysis of Gene Expression Data: Methods and Software. Springer:
New York, 2003.
2. Hidalgo M, Eckhardt SG, Garrett-Mayer E, Clendenin N. Principles of Anticancer Drug Development. Springer: New
York, 2011.
UCHAPTERS IN SCHOLARLY BOOKS AND MONOGRAPHS
1. Garrett ES, Parmigiani G. POE: Statistical Methods for Qualitative Analysis of Gene Expression. In The Analysis of Gene
Expression Data: Methods and Software (eds. G Parmigiani, ES Garrett, RA Irizarry, SL Zeger) Chapter 16, Springer: New
York, 2003.
2. Parmigiani G, Garrett ES, Irizarry RA, Zeger SL. The Analysis of Gene Expression Data: An Overview of Methods and
Software. In The Analysis of Gene Expression Data: Methods and Software (eds. G. Parmigiani, E.S. Garrett, R.A. Irizarry,
S.L. Zeger) Chapter 1, Springer: New York, 2003.
3. Garrett ES. Overview of Standard Clustering Approaches for Gene Microarray Data Analysis. In DNA Microarrays and
Statistical Genomic Techniques: Design, Analyis, and Interpretation of Experiments (eds. D. Allison, M. Beasley, J.
Edwards, G. Page). Chapter 3, Marcel-Dekker: New York, 2006.
4. Garrett ES. Latent Class Analysis. In Encyclopedia of Biopharmaceutical Statistics, ed. Shein-Chung Chow. Marcel
Dekker: New York, 2003.
5. Garrett-Mayer E, Scharpf R. Models for probability of under- and over-expression: The POE scale. In Bayesian Inference
for Gene Expression and Proteomics, ed. K.-A. Do, P. Mueller, M. Vannucci. Chapter 13, Cambridge University Press:
Cambridge, 2006.
6. Garrett-Mayer E, Parmigiani G. Clustering and classification methods for gene expression data analysis. In DNA
Microarrays (Advanced Methods), ed. U. Nuber. Taylor and Francis Group: New York, 2005.
7. Garrett-Mayer, E. Application of Novel Designs in Phase I Trials. In Wiley Encyclopedia of Clinical Trials, ed. L.Sullivan.
8. Garrett-Mayer, E. Adaptive Clinical Trial Design in Oncology. In Oncology Clinical Trials, ed. Kelly & Halabi. New
York: Demos Medical, 2010.
9. Hill EG, Garrett-Mayer E. Basic Biostatistics for the Clinical Trialist. In Principles of Anticancer Drug Development. Ed.
Hidalgo, Eckhardt, Garrett-Mayer, Clendeninn. Springer: New York, 2011.
UNON-PEER REVIEWED ELECTRONIC PUBLICATIONS:
1. HUGarrett ES, Parmigiani GP. A Nested Unsupervised Approach to Identifying Novel Molecular Subtypes. Johns Hopkins
ELIZABETH GARRETT-MAYER PAGE 31 OF 31 MAY 16
University, Dept. of Biostatistics Working Paper 5, October 6, 2003. U
2. HUGarrett ES, Miech R, Owens P, Eaton W, Zeger S. Checking assumptions in latent class regression models via a markov
chain monte carlo estimation approach: an application to depression and socio-economic status. Johns Hopkins University,
Dept. of Biostatistics Working Paper 17, January 15, 2003. U
3. HUCope L, Zhong X, Garrett-Mayer E, Parmigiani G. MergeMaid: R Tools for Merging and Cross-Study Validation of Gene
Expression Data. Johns Hopkins University, Dept. of Biostatistics Working Paper 53, 2004. U
4. HUGarrett-Mayer E, Goodman SN, Hruban RH. The Proportional Odds Model for Assessing Rater Agreement with Multiple
Modalities. Johns Hopkins University, Dept. of Biostatistics Working Paper 64, 2004. U
5. HUGarrett-Mayer E, Parmigiani G, Zhong X, Cope L, Gabrielson E. Cross-study Validation and Combined Analysis of Gene
Expression Microarray Data. Johns Hopkins University, Dept. of Biostatistics Working Paper 65, 2004. U
6. HUGarrett-Mayer E, Parmigiani G. Clustering and Classification Methods for Gene Expression Data Analysis. Johns Hopkins
University, Dept. of Biostatistics Working Paper 70, 2004. U
7. HUGarrett-Mayer E. Understanding the Continual Reassessment Method for Dose Finding Studies: An Overview for Non-
Statisticians. Johns Hopkins University, Dept. of Biostatistics Working Paper 74, 2005. U
8. HUZhong X, Marchionni L, Cope L, Iversen E, Garrett-Mayer E, Gabrielson E, Parmigiani G. Optimized Cross-Study
Analysis of Microarray Based Predictors. Johns Hopkins University, Dept. of Biostatistics Working Paper 129, 2007. U
9. HUSu S-C, Caffo B, Garrett-Mayer E, Bassett S. Modified Test Statistics by Inter-voxel Variance Shrinkage with an
Application to fMRI. Johns Hopkins University, Dept. of Biostatistics Working Paper 138, 2007. U
10. HUCope L, Garrett-Mayer E, Gabrielson E, Parmigiani G. A Measure of Cross-Study. Johns Hopkins University, Dept. of
Biostatistics, Working Paper 146, 2007. U
11. Garrett-Mayer E, Wahlquist AE. A likelihood-based approach to early stopping in single arm phase II clinical trials. MUSC
Department of Public Health Sciences Working Papers 11-001, 2011.
12. O’Connell N, Garrett-Mayer E. Latent variable approach to elicit continuous toxicity scores and severity weights for
multiple toxicities in dose-finding oncology trials. MUSC Department of Public Health Sciences Working Papers 15-001,
2015.
USOFTWARE
1. Garrett ES, Hu J, Parmigiani G, Cope LC, Zhong X. POE: statistical tools for molecular classification using microarrays
(2002) HUhttp://astor.som.jhmi.edu/poe/ U
2. Zhong X, Garrett ES, Cope LC, Parmigiani G. Mergemaid: Merging and visualization tools for cross-study validation of
gene expression analyses (2004) HUhttp://astor.som.jhmi.edu/MergeMaid/ U
C COMMUNITY SERVICE
2010- 2011 Wando High School: Business Alliance Board for the School of Health Sciences, Human and Public
Services. Mt Pleasant, SC.
2013-2014 Senior Student Thesis Mentor, Academic Magnet High School, North Charleston, SC.
2014 – present Carolina Coonhound Rescue, Foster parent to homeless hounds. Charleston, SC.